

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 25 February 1999 (25.02.99)	
International application No. PCT/US98/13551	Applicant's or agent's file reference TUL2APCT
International filing date (day/month/year) 29 June 1998 (29.06.98)	Priority date (day/month/year) 30 June 1997 (30.06.97)
Applicant PHILIPP, Mario, T.	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

25 January 1999 (25.01.99)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Christelle Croci

Telephone No.: (41-22) 338.83.38


From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT
(PCT Rule 71.1)

To:

BAK, Mary E.
Howson and Howson
Spring House Corporate Center
P.O. Box 457
Spring House, PA 19477
ETATS-UNIS D'AMERIQUE



Date of mailing
(day/month/year)

15. 10. 99

Applicant's or agent's file reference
TUL2APCT

IMPORTANT NOTIFICATION

International application No.
PCT/US98/13551

International filing date (day/month/year)
29/06/1998

Priority date (day/month/year)
30/06/1997

Applicant

THE ADMINISTRATORS OF THE TULANE... et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4165

Authorized officer

Vullo, C

Tel. +49 89 2399-8061



PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference TUL2APCT	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US98/13551	International filing date (day/month/year) 29/06/1998	Priority date (day/month/year) 30/06/1997
International Patent Classification (IPC) or national classification and IPC C07K14/20		
Applicant THE ADMINISTRATORS OF THE TULANE... et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 9 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 25/01/1999	Date of completion of this report 15. 10. 99
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer BULCAO DE MELO ..., T Telephone No +49 89 2399 8972 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US98/13551

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-60 as originally filed

Claims, No.:

1-65 as originally filed

Drawings, sheets:

1/6-6/6 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
☒ claims Nos. 38-65.

because:

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US98/13551

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):
- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 38-65.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-37
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-37
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-29, 31, 32 and 34-37
	No:	Claims	30 and 33 (no assessment, see Section V, Item 6)

2. Citations and explanations

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US98/13551

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US98/13551

1. Reference is made to the following documents:

D1: Infection and Immunity, Vol. 64, No. 4, 1996, pages 1259-1264

2. The present International Preliminary Examination Report has been established with the assumption that the **priority date 30/06/97** is validly claimed. Therefore, documents EMBL/GenBank/DDBJ databases, Accession Numbers AF034515 (2 June 1998), AF034525 (2 June 1998), AF034523 (2 June 1998), and AB011063 (13 March 1998), have not been considered to be part of the prior art as defined in the regulations (**Rule 64 (1) and (3) PCT**).

SECTION III

3. The International Search Authority considered that in the absence of a definition of "cassette string protein", the claims concerning said and related subject-matter are not clear and concise (**Article 6 PCT**). The search has been limited to a protein from *Borrelia garinii* strain IP90, having an apparent molecular weight of 39,5 kDa and the sequences disclosed in the application, and related subject-matter. Thus, no examination of the claimed invention for **claims 38-65** was carried out because its subject-matter was found unsearchable. The Search Report and therefore the present International Preliminary Examination Report are restricted to the subject-matter of **claims 1-37**.

SECTION V

4. Novelty (**Article 33(2) PCT**)

The subject-matter of **claims 1-37** does not appear to be disclosed in the prior art as defined in the regulations (**Rule 64 (1)-(3) PCT**).

Therefore, in view of such prior art the subject-matter of said claims has to be regarded as being new (**Article 33 (2) PCT**).

5. Inventive Step (Article 33 (3) PCT)

The **closest prior art** to evaluate the inventiveness of **claims 1-37** is document **D1**. Document D1 discloses several *Borrelia burgdorferi* antigen proteins, such as BmpA, BmpB, BmpC and BmpD, genes encoding said antigens and antibodies directed to said antigens. (See Abstract and page 1259: paragraph bridging left and right hand column).

Starting from **D1**, the underlying **technical problem** to be solved by the present application can be considered to lie in the provision of an alternative *Borrelia burgdorferi* antigen.

The **solution** provided by the Applicant to solve the above problem is a *Borrelia burgdorferi* surface antigen having a molecular mass of 39,500 daltons and comprising the amino acid sequences SEQ ID NO: 2 and SEQ ID NO: 14.

Neither D1 nor any of the cited prior art documents, discloses nor suggests the existence of further *Borrelia burgdorferi* antigens. Therefore, there is no indication in the prior art that would teach the person skilled in the art, with a reasonable expectation of success, to search for and isolate the new *Borrelia burgdorferi* antigen of the present application.

Although the antigen of the present application was eventually identified as BmpA (see page 39, line 10 of the description), further experiments (see pages 40 and 41 of the description) proved that said antigen was not BmpA but a new antigen thereafter referred to as P39,5.

The new *Borrelia* surface antigen of the present invention is abundantly expressed *in vivo* by spirochetes of *B. burgdorferi sensu stricto* strains JD1, and both *in vivo* and *in vitro* by spirochetes *B. garinii* strain IP90.

Unlike other known *Borrelia* antigens, such as OspA and OspB, the new P39,5 surface antigen is functionally characterised by the ability to elicit antibody in animals during the course of a natural infection with *Borrelia* spirochetes, wherein said induced antibodies kill IP90 spirochetes by ADCK (antibody-dependent complement-mediated killing) *in vitro*.

Therefore, in view of the above, the subject-matter of **claims 1-37** has to be regarded as involving an inventive step.

6. Industrial Applicability (Article 33(4) PCT)

- 6.1. The subject-matter of present **claims 1-29, 31, 32 and 34-37** is susceptible of industrial applicability as defined in **Article 33 (4) PCT**.
- 6.2. For the assessment of the present **claims 30 and 33** on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

SECTION VIII

7. The present application does not satisfy the criterion set forth in **Article 6 PCT** because the following claims are not clear.

- 7.1. A nucleic acid sequence (claim 1) and a protein (claim 4), regarded as a chemical products, should be clearly and unambiguously characterized by technical features, e.g. their nucleotide and amino acid sequences and not only by the result to be achieved (cf. **Guidelines CIII 4.7 and 4.7a**).

Moreover, regarding **claim 4**, the characterisation of a protein by its molecular mass is not sufficient to clearly and unambiguously characterise said protein. In addition the value presented for the molecular mass is not clearly defined because there is no indication regarding the method used in its determination.

- 7.2. The following terms and expressions render the respective claims unclear:

"fragment" or "fragment thereof" (**claims 1, 3, 5-7, 9, 10, 14-17, 20, 23, 25-27, 29, 34 and 36**). These terms do not indicate either the length of the fragment, the region/domain of the protein, DNA or antibody to which the fragment corresponds, the function of the fragment, or any particular characteristic/s that the fragment should have.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US98/13551

"allelic variant" (**claims 3, 15**) and "variant" (**claim 26**). These terms do not indicate whether said variants maintain the structural and/or functional characteristics of the sequences/antigens.

"deletion mutant" (**claims 3, 13, 15**) and "deletion protein" (**claims 6, 13**). These expressions do not give any information regarding the type of deletion nor whether the final sequence retains the properties of the initial sequence.

"analog" (**claims 5, 6**), "homolog" (**claims 5, 6**) and "sequence homologous" (**claim 27**). These expressions do not indicate the type and degree of homology (structural and/or functional).

The above mentioned terms and expressions are not suitable to clearly define the scope of said claims because their vagueness makes them entirely opened to individual interpretation.

- 7.3. The term "P39.5" (**claims 1, 3, 4, 7, 9, 10, 12-17, 20, 27, 29, 31, 32, 34 and 36**) render the scope of said claims unclear, because this term is a simple arbitrary designation which is meaningless to the person skilled in the art. Moreover, the applicant is informed that the provision of a name/designation to a protein does not further characterise the protein, because said name/designation is not regarded as a technical feature. The same applies to the terms "P7-1", "P1-1", "P3-1", "P6-1", "P9-1" and "P12-1" (**claims 17, 24, 31 and 32**). Therefore, in order to clarify said claims it should be specified to what these terms refers to.

- 7.4. The subject-matter of **claim 2** is characterised by an ATCC accession number which refers to the deposition of a microorganism (an *E. coli* strain). Therefore, it appears that the wording "composition" is not accurate to define said subject-matter. Moreover, regarding the above said, it appears that the dependency of claim 2 on claim 1 is erroneous.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US98/13551

- 7.5. **Claim 23** lacks clarity because it does not indicate the type of fusion proteins. Dependent **claim 28** lacks clarity because it is not understandable to which individual proteins it refers to.
- 7.6. **Claim 35** lacks clarity because the surface antigen is not specifically indicated.
- 7.7. The subject-matter of **claim 37** is not defined because a compound should be characterised by technical features and not by the method through which it is identified. Consequently, the scope of said claim is so broad that known compounds may fall within said scope.
- 7.8. The subject-matter of **claims 1, 4, 7-14 and 16-37** refers to a general antigen P39,5 or to its encoding nucleic acid, wherein said protein and DNA are not clearly and unambiguously characterised by technical features, e.g. by their amino acid and nucleotide sequences. This renders said claims unclear.
Said claims should therefore be clarified by referring specifically to the *Borrelia* surface antigen of the present application.

SECTION VII

8. Contrary to the requirements of **Rule 5.1(a)(ii) PCT**, the relevant background art disclosed in document **D1** is not mentioned in the description, nor is this document identified therein.

PATENT COOPERATION TREATY

From the:
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

WRITTEN OPINION

(PCT Rule 66)

To:

BAK, Mary E.
Howson and Howson
Spring House Corporate Center
P.O. Box 457
Spring House, PA 19477
ETATS-UNIS D'AMERIQUE

JUN 25 1999

Date of mailing
(day/month/year)

2 1. 06. 99

Applicant's or agent's file reference

TUL2APCT

REPLY DUE

within 3 month(s)
from the above date of mailing

International application No.

PCT/US98/13551

International filing date (day/month/year)

29/06/1998

Priority date (day/month/year)

30/06/1997

International Patent Classification (IPC) or both national classification and IPC

C07K14/20

**ENTERED
DUE 9-21-99**

Applicant

THE ADMINISTRATORS OF THE TULANE... et al.

1. This written opinion is the **first** drawn up by this International Preliminary Examining Authority.

2. This opinion contains indications relating to the following items:

- I ☒ Basis of the opinion
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain document cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

3. The applicant is hereby **invited to reply** to this opinion.

When? See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also: For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: **30/10/1999**.

Name and mailing address of the international preliminary examining authority:



European Patent Office
D-80298 Munich
Tel. (+49-89) 2399-0 Tx: 523656 epmu d
Fax: (+49-89) 2399-4465

Authorized officer / Examiner

BULCAO DE MELO .., T

Formalities officer (incl. extension of time limits)

Vullo, C

Telephone No. (+49-89) 2399 8061



WRITTEN OPINION

International application No. PCT/US98/13551

I. Basis of the opinion

1. This opinion has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".*):

Description, pages:

1-60 as originally filed

Claims, No.:

1-65 as originally filed

Drawings, sheets:

1/6-6/6 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:

- ☐ the entire international application,
- ☒ claims Nos. 38-65,

because:

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

WRITTEN OPINION

International application No. PCT/US98/13551

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 38-65.

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-37 (YES)
Inventive step (IS)	Claims	1-37 (YES)
Industrial applicability (IA)	Claims	30 and 33 (no assessment, see Section V, Item 6)

2. Citations and explanations

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

1. Reference is made to the following documents:

D1: Infection and Immunity, Vol. 64, No. 4, 1996, pages 1259-1264

2. The present written opinion has been established with the assumption that the **priority date** 30/06/97 is validly claimed. Therefore, documents EMBL/GenBank/DDBJ databases, Accession Numbers AF034515 (2 June 1998), AF034525 (2 June 1998), AF034523 (2 June 1998), and AB011063 (13 March 1998), have not been considered to be part of the prior art as defined in the regulations (**Rule 64 (1) and (3) PCT**).

SECTION III

3. The International Search Authority considered that in the absence of a definition of "cassette string protein", the claims concerning said and related subject-matter are not clear and concise (**Article 6 PCT**). The search has been limited to a protein from *Borrelia garinii* strain IP90, having an apparent molecular weight of 39,5 kDa and the sequences disclosed in the application, and related subject-matter. Thus, no examination of the claimed invention for **claims 38-65** was carried out because its subject-matter was found unsearchable. The Search Report and therefore the present written opinion are restricted to the subject-matter of **claims 1-37**.

SECTION V

4. Novelty (**Article 33(2) PCT**)

The subject-matter of **claims 1-37** does not appear to be disclosed in the prior art as defined in the regulations (**Rule 64 (1)-(3) PCT**).

Therefore, in view of such prior art the subject-matter of said claims has to be regarded as being new (**Article 33 (2) PCT**).

5. Inventive Step (Article 33 (3) PCT)

The **closest prior art** to evaluate the inventiveness of **claims 1-37** is document **D1**. Document D1 discloses several *Borrelia burgdorferi* antigen proteins, such as BmpA, BmpB, BmpC and BmpD, genes encoding said antigens and antibodies directed to said antigens. (See Abstract and page 1259: paragraph bridging left and right hand column)

Starting from **D1**, the underlying **technical problem** to be solved by the present application can be considered to lie in the provision of an alternative *Borrelia burgdorferi* antigen.

The **solution** provided by the Applicant to solve the above problem is a *Borrelia burgdorferi* surface antigen having a molecular mass of 39,500 daltons and comprising the amino acid sequences SEQ ID NO: 2 and SEQ ID NO: 14.

Neither D1 nor any of the cited prior art documents, discloses nor suggests the existence of further *Borrelia burgdorferi* antigens. Therefore, there is no indication in the prior art that would teach the person skilled in the art, with a reasonable expectation of success, to search for and isolate the new *Borrelia burgdorferi* antigen of the present application.

Although the antigen of the present application was eventually identified as BmpA (see page 39, line 10 of the description), further experiments (see pages 40 and 41 of the description) proved that said antigen was not BmpA but a new antigen thereafter referred to as P39,5.

The new *Borrelia* surface antigen of the present invention is abundantly expressed *in vivo* by spirochetes of *B. burgdorferi sensu stricto* strains JD1, and both *in vivo* and *in vitro* by spirochetes *B. garinii* strain IP90.

Unlike other known *Borrelia* antigens, such as OspA and OspB, the new P39,5 surface antigen is functionally characterised by the ability to elicit antibody in animals during the course of a natural infection with *Borrelia* spirochetes, wherein said induced antibodies kill IP90 spirochetes by ADCK (antibody-dependent complement-mediated killing) *in vitro*.

Therefore, in view of the above, the subject-matter of **claims 1-37** has to be regarded as involving an inventive step.

6. Industrial Applicability (Article 33(4) PCT)

For the assessment of the present **claims 30 and 33** on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

SECTION VIII

7. The present application does not satisfy the criterion set forth in **Article 6 PCT** because the following claims are not clear.

7.1. A nucleic acid sequence (**claim 1**) and a protein (**claim 4**), regarded as a chemical products, should be clearly and unambiguously characterized by technical features, e.g. their nucleotide and amino acid sequences and not only by the result to be achieved (**cf. Guidelines CIII 4.7 and 4.7a**).

Moreover, regarding **claim 4**, the characterisation of a protein by its molecular mass is not sufficient to clearly and unambiguously characterise said protein. In addition the value presented for the molecular mass is not clearly defined because there is no indication regarding the method used in its determination.

7.2. The following *terms* and *expressions* render the respective claims unclear:

- "fragment" or "fragment thereof" (**claims 1, 3, 5-7, 9, 10, 14-17, 20, 23, 25-27, 29, 34 and 36**). These terms do not indicate either the length of the fragment, the region/domain of the protein, DNA or antibody to which the fragment corresponds, the function of the fragment, or any particular characteristic/s that the fragment should have.
- "allelic variant" (**claims 3, 15**) and "variant" (**claim 26**). These terms do not indicate whether said variants maintain the structural and/or functional characteristics of the sequences/antigens.

**WRITTEN OPINION
SEPARATE SHEET**

International application No. PCT/US98/13551

- "deletion mutant" (claims 3, 13, 15) and "deletion protein" (claims 6, 13). These expressions do not give any information regarding the type of deletion nor whether the final sequence retains the properties of the initial sequence.
- "analog" (claims 5, 6), "homolog" (claims 5, 6) and "sequence homologous" (claim 27). These expressions do not indicate the type and degree of homology (structural and/or functional).

The above mentioned terms and expressions are not suitable to clearly define the scope of said claims because their vagueness makes them entirely opened to individual interpretation.

- 7.3. The term "P39.5" (claims 1, 3, 4, 7, 9, 10, 12-17, 20, 27, 29, 31, 32, 34 and 36) render the scope of said claims unclear, because this term is a simple arbitrary designation which is meaningless to the person skilled in the art. Moreover, the applicant is informed that the provision of a name/designation to a protein does not further characterise the protein, because said name/designation is not regarded as a technical feature. The same applies to the terms "P7-1", "P1-1", "P3-1", "P6-1", "P9-1" and "P12-1" (claims 17, 24, 31 and 32). Therefore, in order to clarify said claims it should be specified to what these terms refers to.
- 7.4. The subject-matter of **claim 2** is characterised by an ATCC accession number which refers to the deposition of a microorganism (an *E. coli* strain). Therefore, it appears that the wording "composition" is not accurate to define said subject-matter. Moreover, regarding the above said, it appears that the dependency of claim 2 on claim 1 is erroneous.
- 7.5. **Claim 23** lacks clarity because it does not indicate the type of fusion proteins. Dependent **claim 28** lacks clarity because it is not understandable to which individual proteins it refers to.
- 7.6. **Claim 35** lacks clarity because the surface antigen is not specifically indicated.

- 7.7. The subject-matter of **claim 37** is not defined because a compound should be characterised by technical features and not by the method through which it is identified. Consequently, the scope of said claim is so broad that known compounds may fall within said scope.
- 7.8. The subject-matter of **claims 1, 4, 7-14 and 16-37** refers to a general antigen P39,5 or to its encoding nucleic acid, wherein said protein and DNA are not clearly and unambiguously characterised by technical features, e.g. by their amino acid and nucleotide sequences. This renders said claims unclear.
Said claims should therefore be clarified by referring specifically to the *Borrelia* surface antigen of the present application.

SECTION VII

8. Contrary to the requirements of **Rule 5.1(a)(ii) PCT**, the relevant background art disclosed in document **D1** is not mentioned in the description, nor is this document identified therein.

***** * *****

9. In case of filing amended claims, the applicant is requested to take account of the above comments.

The attention of the Applicant is drawn to the fact that the application may not be amended in such a way that it contains subject-matter which extends beyond the content of the application as filed (**Article 34 (2)(b) PCT** and **Rule 70.2 (c) PCT**).

In order to facilitate the examination of the conformity of the amended application with the requirements of **Article 34 (2)(b) PCT**, the Applicant is requested to clearly identify the amendments carried out, irrespective of whether they concern amendments by addition, replacement or deletion, and to indicate the passages of the application as filed on which these amendments are based.

The demand must be filed directly with the competent International Preliminary Examining Authority or, if two or more Authorities are competent, with the one chosen by the applicant. The full name or two-letter code of that Authority may be indicated by the applicant on the line below:

IPEA/ EPO

PCT

CHAPTER II

DEMAND

under Article 31 of the Patent Cooperation Treaty:

The undersigned requests that the international application specified below be the subject of international preliminary examination according to the Patent Cooperation Treaty and hereby elects all eligible States (except where otherwise indicated).

For International Preliminary Examining Authority use only	
Identification of IPEA	Date of receipt of DEMAND
Box No. I IDENTIFICATION OF THE INTERNATIONAL APPLICATION	
Applicant's or agent's file reference TUL2APCT	
International application No. PCT/US98/13551	International filing date (day/month/year) 29 June 1998
(Earliest) Priority date (day/month/year) 30 June 1997	
Title of invention Surface Antigens and Proteins Useful in Compositions for the Diagnosis and Prevention of Lyme Disease	
Box No. II APPLICANT(S)	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) The Administrators of the Tulane Educational Fund 1430 Tulane Avenue New Orleans, Louisiana 70112-2699 United States of America	Telephone No.: 504-585-6962 Facsimile No.: 504-584-2473 Teleprinter No.:
State (that is, country) of nationality: United States of America	State (that is, country) of residence: United States of America
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) Philipp, Mario T. 248 Shaunell Drive Mandeville, Louisiana 70448 United States of America	
State (that is, country) of nationality: Germany	State (that is, country) of residence: United States of America
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)	
State (that is, country) of nationality:	State (that is, country) of residence:
<input type="checkbox"/> Further applicants are indicated on a continuation sheet.	

Box No. III AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCEThe following person is ☒ agent ☐ common representativeand ☒ has been appointed earlier and represents the applicant(s) also for international preliminary examination.☐ is hereby appointed and any earlier appointment of (an) agent(s)/common representative is hereby revoked.☐ is hereby appointed, specifically for the procedure before the International Preliminary Examining Authority, in addition to the agent(s)/common representative appointed earlier.Name and address: (Family name followed by given name: for a legal entity, full official designation.
The address must include postal code and name of country.)Bak, Mary E.
Howson and Howson
Spring House Corporate Center
P.O. Box 457
Spring House, Pennsylvania 19477
United States of America

Telephone No.:

215-540-9200

Facsimile No.:

215-540-5818

Teleprinter No.:

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.**Box No. IV BASIS FOR INTERNATIONAL PRELIMINARY EXAMINATION****Statement concerning amendments:***

1. The applicant wishes the international preliminary examination to start on the basis of:

☒ the international application as originally filed

the description

☐ as originally filed☐ as amended under Article 34

the claims

☐ as originally filed☐ as amended under Article 19 (together with any accompanying statement)☐ as amended under Article 34

the drawings

☐ as originally filed☐ as amended under Article 342. ☐ The applicant wishes any amendment to the claims under Article 19 to be considered as reversed.3. ☐ The applicant wishes the start of the international preliminary examination to be postponed until the expiration of 20 months from the priority date unless the International Preliminary Examining Authority receives a copy of any amendments made under Article 19 or a notice from the applicant that he does not wish to make such amendments (Rule 69.1(d)). (This check-box may be marked only where the time limit under Article 19 has not yet expired.)

* Where no check-box is marked, international preliminary examination will start on the basis of the international application as originally filed or, where a copy of amendments to the claims under Article 19 and/or amendments of the international application under Article 34 are received by the International Preliminary Examining Authority before it has begun to draw up a written opinion or the international preliminary examination report, as so amended.

Language for the purposes of international preliminary examination: English☒ which is the language in which the international application was filed.☐ which is the language of a translation furnished for the purposes of international search.☐ which is the language of publication of the international application.☐ which is the language of the translation (to be) furnished for the purposes of international preliminary examination.**Box No. V ELECTION OF STATES**

The applicant hereby elects all eligible States (that is, all States which have been designated and which are bound by Chapter II of the PCT)

excluding the following States which the applicant wishes not to elect:

Box No. VI CHECK LIST

The demand is accompanied by the following elements, in the language referred to in Box No. IV, for the purposes of international preliminary examination:

- | | | |
|--|---|--------|
| 1. translation of international application | : | sheets |
| 2. amendments under Article 34 | : | sheets |
| 3. copy (or, where required, translation) of amendments under Article 19 | : | sheets |
| 4. copy (or, where required, translation) of statement under Article 19 | : | sheets |
| 5. letter | : | sheets |
| 6. other (specify) | : | sheets |

For International Preliminary Examining Authority use only

received not received

<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>

The demand is also accompanied by the item(s) marked below:

- | | |
|--|---|
| 1. <input checked="" type="checkbox"/> fee calculation sheet | 4. <input type="checkbox"/> statement explaining lack of signature |
| 2. <input type="checkbox"/> separate signed power of attorney | 5. <input type="checkbox"/> nucleotide and or amino acid sequence listing in computer readable form |
| 3. <input type="checkbox"/> copy of general power of attorney; reference number, if any: | 6. <input type="checkbox"/> other (specify): |

Box No. VII SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the demand).

By: Mary E. Bak
Mary E. Bak
Attorney for Applicants

For International Preliminary Examining Authority use only

1. Date of actual receipt of DEMAND:

2. Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b):

3. ☐ The date of receipt of the demand is AFTER the expiration of 19 months from the priority date and item 4 or 5, below, does not apply.

☐ The applicant has been informed accordingly.

4. ☐ The date of receipt of the demand is WITHIN the period of 19 months from the priority date as extended by virtue of Rule 80.5.

5. ☐ Although the date of receipt of the demand is after the expiration of 19 months from the priority date, the delay in arrival is EXCUSED pursuant to Rule 82.

For International Bureau use only

Demand received from IPEA on:

See Notes to the demand form

PATENT COOPERATION TREATY

PCT

REC'D 20 OCT 1999

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference TUL2APCT	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US98/13551	International filing date (day/month/year) 29/06/1998	Priority date (day/month/year) 30/06/1997
International Patent Classification (IPC) or national classification and IPC C07K14/20		
Applicant THE ADMINISTRATORS OF THE TULANE... et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 9 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 25/01/1999	Date of completion of this report 15. 10. 99
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer BULCAO DE MELO ..., T Telephone No. +49 89 2399 8972 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US98/13551

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-60 as originally filed

Claims, No.:

1-65 as originally filed

Drawings, sheets:

1/6-6/6 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
☒ claims Nos. 38-65.

because:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US98/13551

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):
- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 38-65.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims 1-37
	No: Claims
Inventive step (IS)	Yes: Claims 1-37
	No: Claims
Industrial applicability (IA)	Yes: Claims 1-29, 31, 32 and 34-37
	No: Claims 30 and 33 (no assessment, see Section V, Item 6)

2. Citations and explanations

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US98/13551

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US98/13551

1. Reference is made to the following documents:

D1: Infection and Immunity, Vol. 64, No. 4, 1996, pages 1259-1264

2. The present International Preliminary Examination Report has been established with the assumption that the **priority date** 30/06/97 is validly claimed. Therefore, documents EMBL/GenBank/DDBJ databases, Accession Numbers AF034515 (2 June 1998), AF034525 (2 June 1998), AF034523 (2 June 1998), and AB011063 (13 March 1998), have not been considered to be part of the prior art as defined in the regulations (**Rule 64 (1) and (3) PCT**).

SECTION III

3. The International Search Authority considered that in the absence of a definition of "cassette string protein", the claims concerning said and related subject-matter are not clear and concise (**Article 6 PCT**). The search has been limited to a protein from *Borrelia garinii* strain IP90, having an apparent molecular weight of 39,5 kDa and the sequences disclosed in the application, and related subject-matter.
- Thus, no examination of the claimed invention for **claims 38-65** was carried out because its subject-matter was found unsearchable.
- The Search Report and therefore the present International Preliminary Examination Report are restricted to the subject-matter of **claims 1-37**.

SECTION V

4. Novelty (**Article 33(2) PCT**)

The subject-matter of **claims 1-37** does not appear to be disclosed in the prior art as defined in the regulations (**Rule 64 (1)-(3) PCT**).

Therefore, in view of such prior art the subject-matter of said claims has to be regarded as being new (**Article 33 (2) PCT**).

5. Inventive Step (Article 33 (3) PCT)

The **closest prior art** to evaluate the inventiveness of **claims 1-37** is document **D1**. Document D1 discloses several *Borrelia burgdorferi* antigen proteins, such as BmpA, BmpB, BmpC and BmpD, genes encoding said antigens and antibodies directed to said antigens. (See Abstract and page 1259: paragraph bridging left and right hand column).

Starting from **D1**, the underlying **technical problem** to be solved by the present application can be considered to lie in the provision of an alternative *Borrelia burgdorferi* antigen.

The **solution** provided by the Applicant to solve the above problem is a *Borrelia burgdorferi* surface antigen having a molecular mass of 39,500 daltons and comprising the amino acid sequences SEQ ID NO: 2 and SEQ ID NO: 14.

Neither D1 nor any of the cited prior art documents, discloses nor suggests the existence of further *Borrelia burgdorferi* antigens. Therefore, there is no indication in the prior art that would teach the person skilled in the art, with a reasonable expectation of success, to search for and isolate the new *Borrelia burgdorferi* antigen of the present application.

Although the antigen of the present application was eventually identified as BmpA (see page 39, line 10 of the description), further experiments (see pages 40 and 41 of the description) proved that said antigen was not BmpA but a new antigen thereafter referred to as P39,5.

The new *Borrelia* surface antigen of the present invention is abundantly expressed *in vivo* by spirochetes of *B. burgdorferi sensu stricto* strains JD1, and both *in vivo* and *in vitro* by spirochetes *B. garinii* strain IP90.

Unlike other known *Borrelia* antigens, such as OspA and OspB, the new P39,5 surface antigen is functionally characterised by the ability to elicit antibody in animals during the course of a natural infection with *Borrelia* spirochetes, wherein said induced antibodies kill IP90 spirochetes by ADCK (antibody-dependent complement-mediated killing) *in vitro*.

Therefore, in view of the above, the subject-matter of **claims 1-37** has to be regarded as involving an inventive step.

6. Industrial Applicability (Article 33(4) PCT)

- 6.1. The subject-matter of present **claims 1-29, 31, 32 and 34-37** is susceptible of industrial applicability as defined in **Article 33 (4) PCT**.
- 6.2. For the assessment of the present **claims 30 and 33** on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

SECTION VIII

7. The present application does not satisfy the criterion set forth in **Article 6 PCT** because the following claims are not clear.

- 7.1. A nucleic acid sequence (**claim 1**) and a protein (**claim 4**), regarded as a chemical products, should be clearly and unambiguously characterized by technical features, e.g. their nucleotide and amino acid sequences and not only by the result to be achieved (**cf. Guidelines CIII 4.7 and 4.7a**).

Moreover, regarding **claim 4**, the characterisation of a protein by its molecular mass is not sufficient to clearly and unambiguously characterise said protein. In addition the value presented for the molecular mass is not clearly defined because there is no indication regarding the method used in its determination.

- 7.2. The following terms and expressions render the respective claims unclear:

"fragment" or "fragment thereof" (**claims 1, 3, 5-7, 9, 10, 14-17, 20, 23, 25-27, 29, 34 and 36**). These terms do not indicate either the length of the fragment, the region/domain of the protein, DNA or antibody to which the fragment corresponds, the function of the fragment, or any particular characteristic/s that the fragment should have.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US98/13551

"allelic variant" (**claims 3, 15**) and "variant" (**claim 26**). These terms do not indicate whether said variants maintain the structural and/or functional characteristics of the sequences/antigens.

"deletion mutant" (**claims 3, 13, 15**) and "deletion protein" (**claims 6, 13**). These expressions do not give any information regarding the type of deletion nor whether the final sequence retains the properties of the initial sequence.

"analog" (**claims 5, 6**), "homolog" (**claims 5, 6**) and "sequence homologous" (**claim 27**). These expressions do not indicate the type and degree of homology (structural and/or functional).

The above mentioned terms and expressions are not suitable to clearly define the scope of said claims because their vagueness makes them entirely opened to individual interpretation.

7.3. The term "P39.5" (**claims 1, 3, 4, 7, 9, 10, 12-17, 20, 27, 29, 31, 32, 34 and 36**) render the scope of said claims unclear, because this term is a simple arbitrary designation which is meaningless to the person skilled in the art.

Moreover, the applicant is informed that the provision of a name/designation to a protein does not further characterise the protein, because said name/designation is not regarded as a technical feature.

The same applies to the terms "P7-1", "P1-1", "P3-1", "P6-1", "P9-1" and "P12-1" (**claims 17, 24, 31 and 32**).

Therefore, in order to clarify said claims it should be specified to what these terms refers to.

7.4. The subject-matter of **claim 2** is characterised by an ATCC accession number which refers to the deposition of a microorganism (an *E. coli* strain). Therefore, it appears that the wording "composition" is not accurate to define said subject-matter. Moreover, regarding the above said, it appears that the dependency of claim 2 on claim 1 is erroneous.

- 7.5. **Claim 23** lacks clarity because it does not indicate the type of fusion proteins. Dependent **claim 28** lacks clarity because it is not understandable to which individual proteins it refers to.
- 7.6. **Claim 35** lacks clarity because the surface antigen is not specifically indicated.
- 7.7. The subject-matter of **claim 37** is not defined because a compound should be characterised by technical features and not by the method through which it is identified. Consequently, the scope of said claim is so broad that known compounds may fall within said scope.
- 7.8. The subject-matter of **claims 1, 4, 7-14 and 16-37** refers to a general antigen P39,5 or to its encoding nucleic acid, wherein said protein and DNA are not clearly and unambiguously characterised by technical features, e.g. by their amino acid and nucleotide sequences. This renders said claims unclear.
Said claims should therefore be clarified by referring specifically to the *Borrelia* surface antigen of the present application.

SECTION VII

8. Contrary to the requirements of **Rule 5.1(a)(ii) PCT**, the relevant background art disclosed in document **D1** is not mentioned in the description, nor is this document identified therein.

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

(PCT Rule 44.1)

To:

Howson and Howson
Attn. BAK, M.
Spring House Corporate Cntr.,
P.O. Box 457
Spring House, PA 19477
UNITED STATES OF AMERICA

RECEIVED
NOV 25 1998

ENTERED
DUE 1-13-99

Date of mailing
(day/month/year) 13/11/1998

Applicant's or agent's file reference
TUL2APCT

FOR FURTHER ACTION See paragraphs 1 and 4 below

International application No.
PCT/US 98/ 13551

International filing date
(day/month/year) 29/06/1998

Applicant

THE ADMINISTRATORS OF THE TULANE EDUC.et al.

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicants's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90 bis.1 and 90 bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mireille Claudepierre

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0465204 A2	08/01/92	AU 8014691 A	09/01/92
		CA 2046025 A	07/01/92
		JP 4297424 A	21/10/92
		PT 98202 A	29/05/92

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos. 1-65

As no functional or structural property shared by P39.5 proteins from strains other than *Borrelia garinii* IP90 is disclosed and in the absence of a definition of "cassette string protein", the claims are not considered to be clear and concise, see PCT-Article 6.

The search has been limited to a protein from *Borrelia garinii* strain IP90 having a apparent molecular mass of 39,5 kDa, and the sequences disclosed. Accordingly, the search concerning related subject-matters has been limited to the subjects related to the searched proteins.

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference TUL2APCT	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 98/ 13551	International filing date (day/month/year) 29/06/1998	(Earliest) Priority Date (day/month/year) 30/06/1997
Applicant THE ADMINISTRATORS OF THE TULANE EDUC.et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.
☒ It is also accompanied by a copy of each prior art document cited in this report.

- ☒ Certain claims were found unsearchable (see Box I).
- ☐ Unity of invention is lacking (see Box II).
- ☒ The international application contains disclosure of a **nucleotide and/or amino acid sequence listing** and the international search was carried out on the basis of the sequence listing
 - ☒ filed with the international application.
 - ☐ furnished by the applicant separately from the international application,
 - ☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.
 - ☐ Transcribed by this Authority
- With regard to the title,
 - ☒ the text is approved as submitted by the applicant.
 - ☐ the text has been established by this Authority to read as follows:
- With regard to the abstract,
 - ☒ the text is approved as submitted by the applicant.
 - ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International Search Report, submit comments to this Authority.
- The figure of the drawings to be published with the abstract is:

Figure No.
 - ☐ as suggested by the applicant.
 - ☐ because the applicant failed to suggest a figure.
 - ☐ because this figure better characterizes the invention.

☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 13551

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 30,33 and 62
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.

2. ☒ Claims Nos.: 1-65
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:

Please see FURTHER INFORMATION SHEET

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

1

International application No.

PCT/US 98/13551

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 14/20, A61K 39/02, C12N 15/31
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, C12N, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Cell., Volume 89, No 2, April 1997, Jing-Ren Zhang et al, "Antigenic Variation in Lyme Disease Borreliae by Promiscuous Recombination of VMP-like Sequence Cassettes"	1-3,6-65
X	EP 0465204 A2 (AMERICAN HOME PRODUCTS CORPORATION), 8 January 1992 (08.01.92), see claims and the whole document	1-2,4-6,23, 30,35,54-59, 61-62
A	Infection and Immunity, Volume 64, No 4, April 1996, Ramesh Ramamoorthy et al, "Molecular Characterization, Genomic Arrangement, and Expression of bmpD, a New Member of the bmp Class of Genes Encoding Membrane Proteins of Borrelia burgdorferi" page 1259 - page 1264	1-6

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

27 October 1998

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL 2280 HV Rijswijk

Date of mailing of the international search report

13. 11. 98

Authorized officer

DATRIK ANDERSSON

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/13551

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Zhang J.-R., et al: "Kinetics and in vivo induction of vlsE antigenic variation in <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ databases. Accession no. AF034515, 2 june 1998 --	1-3,6-65
P,X	Kawabata H. et al: "Genetic and immunological analyses of Vls (VMP-like sequences) of <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ databases. Accession no. AB011063, 13 March 1998 --	1-3,6-65
P,X	Zhang J.-R. et al: "Kinetics and in vivo induction of vlsE antigenic variation in <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ databases. Accession no. AF034525, 2 june 1998 --	1-3,6-65
P,X	Zhang J.R. et al: "Kinetics and In vivo induction of genetic variation of vlsE in <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ Databases. Accession no. AF034523, 2 june 1998 -- -----	1-3,6-65

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference TUL2APCT	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 98/ 13551	International filing date (day/month/year) 29/06/1998	(Earliest) Priority Date (day/month/year) 30/06/1997
Applicant THE ADMINISTRATORS OF THE TULANE EDUC.et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☒ Certain claims were found unsearchable (see Box I).

2. ☐ Unity of invention is lacking (see Box II).

3. ☒ The international application contains disclosure of a **nucleotide and/or amino acid sequence listing** and the international search was carried out on the basis of the sequence listing

☒ filed with the international application.

☐ furnished by the applicant separately from the international application,

☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.

☐ Transcribed by this Authority

4. With regard to the title, ☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International Search Report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is:

Figure No. ☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 13551

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 30,33 and 62
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.: 1-65
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:

Please see FURTHER INFORMATION SHEET
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos. 1-65

As no functional or structural property shared by P39.5 proteins from strains other than *Borrelia garinii* IP90 is disclosed and in the absence of a definition of "cassette string protein", the claims are not considered to be clear and concise, see PCT-Article 6.

The search has been limited to a protein from *Borrelia garinii* strain IP90 having a apparent molecular mass of 39,5 kDa, and the sequences disclosed. Accordingly, the search concerning related subject-matters has been limited to the subjects related to the searched proteins.

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 14/20, A61K 39/02, C12N 15/31

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, C12N, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Cell., Volume 89, No 2, April 1997, Jing-Ren Zhang et al, "Antigenic Variation in Lyme Disease <i>Borrelia</i> by Promiscuous Recombination of VMP-like Sequence Cassettes" --	1-3,6-65
X	EP 0465204 A2 (AMERICAN HOME PRODUCTS CORPORATION), 8 January 1992 (08.01.92), see claims and the whole document --	1-2,4-6,23, 30,35,54-59, 61-62
A	Infection and Immunity, Volume 64, No 4, April 1996, Ramesh Ramamoorthy et al, "Molecular Characterization, Genomic Arrangement, and Expression of bmpD, a New Member of the bmp Class of Genes Encoding Membrane Proteins of <i>Borrelia burgdorferi</i> " page 1259 - page 1264 --	1-6

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

27 October 1998

Date of mailing of the international search report

13. 11. 98

Name and mailing address of the ISA/



European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

PATRICK ANDERSSON

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Zhang J.-R., et al: "Kinetics and in vivo induction of vlsE antigenic variation in <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ databases. Accession no. AF034515, 2 june 1998 --	1-3,6-65
P,X	Kawabata H. et al: "Genetic and immunological analyses of Vls (VMP-like sequences) of <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ databases. Accession no. AB011063, 13 March 1998 --	1-3,6-65
P,X	Zhang J.-R. et al: "Kinetics and in vivo induction of vlsE antigenic variation in <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ databases. Accession no. AF034525, 2 june 1998 --	1-3,6-65
P,X	Zhang J.R. et al: "Kinetics and In vivo induction of genetic variation of vlsE in <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ Databases. Accession no. AF034523, 2 june 1998 -- -----	1-3,6-65

INTERNATIONAL SEARCH REPORT

Information on patent family members

05/10/98

International application No.

PCT/US 98/13551

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0465204 A2	08/01/92	AU 8014691 A	09/01/92
		CA 2046025 A	07/01/92
		JP 4297424 A	21/10/92
		PT 98202 A	29/05/92

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/13551

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 14/20, A61K 39/02, C12N 15/31
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, C12N, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Cell., Volume 89, No 2, April 1997, Jing-Ren Zhang et al, "Antigenic Variation in Lyme Disease Borreliae by Promiscuous Recombination of VMP-like Sequence Cassettes"	1-3,6-65
X	EP 0465204 A2 (AMERICAN HOME PRODUCTS CORPORATION), 8 January 1992 (08.01.92), see claims and the whole document	1-2,4-6,23, 30,35,54-59, 61-62
A	Infection and Immunity, Volume 64, No 4, April 1996, Ramesh Ramamoorthy et al, "Molecular Characterization, Genomic Arrangement, and Expression of bmpD, a New Member of the bmp Class of Genes Encoding Membrane Proteins of Borrelia burgdorferi" page 1259 - page 1264	1-6

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

27 October 1998

Name and mailing address of the ISA/



European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Date of mailing of the international search report

13. 11. 98

Authorized officer

PATRICK ANDERSSON

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/13551

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Zhang J.-R., et al: "Kinetics and in vivo induction of vlsE antigenic variation in <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ databases. Accession no. AF034515, 2 June 1998 --	1-3,6-65
P,X	Kawabata H. et al: "Genetic and immunological analyses of Vls (VMP-like sequences) of <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ databases. Accession no. AB011063, 13 March 1998 --	1-3,6-65
P,X	Zhang J.-R. et al: "Kinetics and in vivo induction of vlsE antigenic variation in <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ databases. Accession no. AF034525, 2 June 1998 --	1-3,6-65
P,X	Zhang J.R. et al: "Kinetics and In vivo induction of genetic variation of vlsE in <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ Databases. Accession no. AF034523, 2 June 1998 -- -----	1-3,6-65

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 13551

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 30,33 and 62
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.: 1-65
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:

Please see FURTHER INFORMATION SHEET
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos. 1-65

As no functional or structural property shared by P39.5 proteins from strains other than *Borrelia garinii* IP90 is disclosed and in the absence of a definition of "cassette string protein", the claims are not considered to be clear and concise, see PCT-Article 6.

The search has been limited to a protein from *Borrelia garinii* strain IP90 having a apparent molecular mass of 39,5 kDa, and the sequences disclosed. Accordingly, the search concerning related subject-matters has been limited to the subjects related to the searched proteins.

Information on page family members

PCT/US 98/13551

Patent document
cited in search report

Publication date

Patent family member(s)Publication
date

EP 0465204 A2

08/01/92

AU	8014691	A
CA	2046025	A
JP	4297424	A
PT	98202	A

09/01/92

07/01/92

21/10/92

29/05/92

1/6





FIG. 1

2 / 6



Blocks	%Identity	
IA vs. IB	70%	
IIA vs. IIB	91%	
A vs. B	84%	
B vs. C	90%	

■ Unique Region

FIG. 2

3/6




FIG. 3

4/6




FIG. 4

5/6




FIG. 5

	JD-1	B-31	IP-90
kDa	123	123	123

97.4-
66.2-
45.0-
31.0-
21.5-
14.4-




FIG. 6

MICROORGANISMS

Optional Sheet in connection with the microorganism referred to on page 10, line 7 of the descriptionA. IDENTIFICATION OF DEPOSIT: E. coli SURE 7-1 IP90Further deposits are identified on an additional sheet ☒

Name of depository institution *

American Type Culture Collection

Address of depository institution (including postal code and country) *

10801 University Boulevard
Manassas, Virginia 20110-2209 USA

Date of deposit *

June 27, 1997

Accession Number *

98478

B. ADDITIONAL INDICATIONS * (leave blank if not applicable). This information is continued on a separate attached sheet ☐

C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE * (if the indications are not for all designated States)

D. SEPARATE FURNISHING OF INDICATIONS * (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")

E. ☒ This sheet was received with the international application when filed (to be checked by the receiving Office)

(Authorized Officer)

Melvin Brooks

☐ The date of receipt (from the applicant) by the International Bureau is

was

(Authorized Officer)

09445803 121399

(Authorized Officer)

SUBSTITUTE SHEET (RULE 26)

MICROORGANISMSOptional Sheet in connection with the microorganism referred to on page 10, line 13-14 of the description:**A. IDENTIFICATION OF DEPOSIT:** E. coli SURE 3-1 IP90Further deposits are identified on an additional sheet ☒:

Name of depositary institution:

American Type Culture Collection

Address of depositary institution (including postal code and country):

10801 University Boulevard
Manassas, Virginia 20110-2209 USA

Date of deposit:

June 11, 1998

Accession Number:

98769**B. ADDITIONAL INDICATIONS:** (leave blank if not applicable). This information is continued on a separate attached sheet ☐**C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE:** (If the indications are not for all designated States)**D. SEPARATE FURNISHING OF INDICATIONS:** (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later: (Specify the general nature of the indications e.g., "Accession Number of Deposit")

E. ☒ This sheet was received with the international application when filed (to be checked by the receiving Office)**MELVIN S. BROOKS SR.**
INTERNATIONAL DIVISION
703-303-5163 MSB

(Authorized Officer)

☐ The date of receipt (from the applicant) by the International Bureau is:

was

(Authorized Officer)

MICROORGANISMSOptional Sheet in connection with the microorganism referred to on page 10, line 13-14 of the description :**A. IDENTIFICATION OF DEPOSIT :** E. coli SURE 6-1 IP90Further deposits are identified on an additional sheet ☒ :

Name of depository institution :

American Type Culture Collection

Address of depository institution (including postal code and country) :

10801 University Boulevard
Manassas, Virginia 20110-2209 USA

Date of deposit :

June 11, 1998

Accession Number :

98770**B. ADDITIONAL INDICATIONS :** (leave blank if not applicable). This information is continued on a separate attached sheet ☐**C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE :** (If the indications are not for all designated States)**D. SEPARATE FURNISHING OF INDICATIONS :** (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")

E. ☒ This sheet was received with the international application when filed (to be checked by the receiving Office)**MELVIN S. BROOKS SR.**
INTERNATIONAL DIVISION(Authorized Officer) 703-305-5163

MSB

☐ The date of receipt (from the applicant) by the International Bureau is :

was

(Authorized Officer)

MICROORGANISMS

Optional Sheet in connection with the microorganism referred to on page 10, line 13-14 of the description *A. IDENTIFICATION OF DEPOSIT: E. coli SURE 9-1 IP90Further deposits are identified on an additional sheet ☒

Name of depository institution *

American Type Culture Collection

Address of depository institution (including postal code and country) *

10801 University Boulevard
Manassas, Virginia 20110-2209 USA

Date of deposit *

June 11, 1998

Accession Number *

98771

B. ADDITIONAL INDICATIONS * (leave blank if not applicable). This information is continued on a separate attached sheet ☐

C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE * (If the indications are not for all designated States)

D. SEPARATE FURNISHING OF INDICATIONS * (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")

E. ☒ This sheet was received with the international application when filed (to be checked by the receiving Office)MELVIN S. BROOKS SR.
INTERNATIONAL DIVISION
703-305-5163

(Authorized Officer)

☐ The date of receipt (from the applicant) by the International Bureau is

MJD

was

(Authorized Officer)

MICROORGANISMSOptional Sheet in connection with the microorganism referred to on page 10, line 13-14 of the description ***A. IDENTIFICATION OF DEPOSIT :** E. coli SURE 12-1 IP90Further deposits are identified on an additional sheet ☒ *

Name of depositary institution *

American Type Culture Collection

Address of depositary institution (including postal code and country) *

10801 University Boulevard
Manassas, Virginia 20110-2209 USA

Date of deposit *

June 11, 1998

Accession Number *

98772**B. ADDITIONAL INDICATIONS :** (leave blank if not applicable). This information is continued on a separate attached sheet ☐**C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE :** (If the indications are not for all designated States)**D. SEPARATE FURNISHING OF INDICATIONS :** (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")

E. ☒ This sheet was received with the international application when filed (to be checked by the receiving Office)**MELVIN S. BROOKS SR.**
INTERNATIONAL DIVISION
(Authorized Officer) **703-305-5163** **MSA**☐ The date of receipt (from the applicant) by the International Bureau is:

was

(Authorized Officer)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/20, A61K 39/02, C12N 15/31		A1	(11) International Publication Number: WO 99/00413
			(43) International Publication Date: 7 January 1999 (07.01.99)
(21) International Application Number: PCT/US98/13551		(81) Designated States: AU, BR, CA, CN, CZ, HU, ID, IL, JP, KR, MX, NO, NZ, PL, TR, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 29 June 1998 (29.06.98)			
(30) Priority Data: 60/051,271 30 June 1997 (30.06.97) US		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/051,271 (CIP) Filed on 30 June 1997 (30.06.97)			
(71) Applicant (for all designated States except US): THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND [US/US]; 1430 Tulane Avenue, New Orleans, LA 70112-2699 (US).			
(72) Inventor; and (75) Inventor/Applicant (for US only): PHILIPP, Mario, T. [DE/US]; 248 Shaunell Drive, Mandeville, LA 70448 (US).			
(74) Agents: BAK, Mary, E. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).			
(54) Title: SURFACE ANTIGENS AND PROTEINS USEFUL IN COMPOSITIONS FOR THE DIAGNOSIS AND PREVENTION OF LYME DISEASE			
(57) Abstract <p>A novel isolated <i>Borrelia burgdorferi</i> sensu lato surface antigen is characterized by a relative molecular mass of 39.5 kDa. This antigen is expressed <i>in vitro</i> by spirochetes of a <i>B. burgdorferi</i> sensu lato strain. This antigen induces antibodies which kill spirochetes of a <i>B. burgdorferi</i> sensu lato strain by ADCK <i>in vitro</i>. Novel <i>Borrelia</i> cassette string protein or fragments thereof are also useful, as is the P39.5 protein in diagnosing Lyme disease and in compositions for treatment or prophylaxis thereof.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

G/PRTS

09 / 4 4 5 8 0 3

420 Rec'd PCT/PTO 13 DEC 1999

SURFACE ANTIGENS AND PROTEINS
USEFUL IN COMPOSITIONS FOR THE DIAGNOSIS
AND PREVENTION OF LYME DISEASE

5 This invention was funded in part by the National Institutes of Health Grant Nos. ROI AI35027 and RR/AE00164-32. The United States government has certain rights in this invention.

Field of the Invention

10 The present invention relates generally to the field of pharmaceutical and diagnostic compositions useful in the diagnosis, treatment and prophylaxis of Lyme borreliosis. More specifically, the invention provides an isolated natural surface antigen of *Borellia* and antibodies thereto for use in the diagnosis, treatment or prevention of Lyme disease.

Background of the Invention

15 *Borrelia burgdorferi* (sensu lato) is a generic term which encompasses several *Borrelia* species associated with, and believed to be, the causative agent of Lyme borreliosis (Lyme disease): *B. burgdorferi* sensu stricto, *B. garinii*, and *B. afzelii*. This disease is transmitted by the bite of various species of *Ixodes* ticks carrying the spirochete. The main reservoir of the infection in the United States is the white footed mouse, *Peromyscus leucopus*, and the infection can be transmitted to
20 many mammalian species including dogs, cats, and man [J. G. Donahue, *et al*, Am. J. Trop. Med. Hyg., 36:92-96 (1987); R. T. Green, *et al*, J. Clin. Micro., 26:648-653 (1988)]. Despite the presence of an active immune response, the disease persists for years in patients. Such persistence is postulated to be the result, at least in part, of antigenic variation in the bacterial proteins [J.R. Zhang *et al*, Cell, 89:275-285
25 (1997)].

The diagnosis of Lyme disease in humans and animals has been compromised by the lack of definitive serology leading to rapid and accurate testing. Current diagnostic tests suffer from low sensitivity and specificity, as illustrated by a recent survey of diagnostic laboratories' performance issued by the Wisconsin State

Laboratory of Hygiene [L. Bakken et al, J. Clin. Microbiol., 35:537 (1997)]. A simple, sensitive and specific diagnostic composition and method for early detection of Lyme disease is needed in the art.

Publications relating to proteins and polypeptides of *Borrelia*

- 5 *burgdorferi* have suggested their use as diagnostic or pharmaceutical agents. Such proteins and polypeptides include outer surface proteins A and B (OspA and OspB), flagellin, and other proteins designated P21, P39, P66, and P83 according to their estimated molecular weights [A. G. Barbour et al, Infect. Immun., 45:94-100 (1984); W. J. Simpson et al, J. Clin. Microbiol., 28:1329-1337 (1990); K. Hansen et al, Infect. Immun., 56:2047-2053 (1988); K. Hansen et al, Infect. J. Clin. Microbiol., 26:338-346 (1988); B. Wilske et al, Zentral. Bakteriell. Parasitenkd. Infektionshkr. Hyg. Abt. 1 Orig. Reihe. A., 263:92-102 (1986); D. W. Dorward et al, J. Clin. Microbiol., 29:1162-1170 (1991); published NTIS US patent application No. 485,551; European patent application No. 465,204, published January 8, 1992; 15 International Patent Application No. PCT/US91/01500, published September 19, 1991; International Patent Application No. PCT/EP90/02282, published July 11, 1991; International Patent Application No. PCT/DK89/00248, published May 3, 1990; International patent application No. WO92/00055, published January 9, 1992.

- A preferred protein candidate for a vaccine is OspA [M. Philipp et al, 20 J. Spirochetal and Tick-borne Diseases, 3:67-79 (1996)]. The expression of OspA is either abrogated or down-regulated when the spirochetes are en route from the tick's midgut to the salivary glands, as blood feeding is taking place [A. DeSilva et al, J. Exp. Med., 183:271-275 (1996)]. This phenomenon generates potential problems that may diminish the OspA vaccine's efficacy. Spirochetal attrition may occur only 25 within the tick midgut [A. DeSilva et al, cited above] and not upon infection of the vertebrate host. Because the saliva of *Ixodes scapularis* contains a decomplementing factor [T. Mather et al, "Ixodes saliva: vector competence for *Borrelia burgdorferi* and potential vaccine strategies", in VII International Congress on Lyme Borreliosis, San Francisco, CA (1996)], spirochetal attrition within the tick's midgut might occur 30 via a mechanism involving only antibody and not complement.

Although the mode of action of antibody-dependent killing is not fully understood, it appears to be a less efficient mechanism of killing than that mediated by antibody and complement, acting together [M. Sole *et al*, Infect. Immunol., 66:2540-2546 (1998)]. Thus, it may permit evasion from the midgut of those spirochetes that have a low surface density of OspA. Indeed, although OspA is an abundant *B. burgdorferi* protein, only a minor fraction of OspA molecules is exposed on the outer surface of the spirochete [D. Cox *et al*, Proc. Natl. Acad. Sci., 93:7973-7978 (1996)]. Thus, small variations in the absolute number of OspA surface molecules may cause significant differences in the spirochete attrition rate and make it possible for a fraction of the resident spirochetes to abscond to the salivary glands.

OspA escape mutants will readily avoid killing altogether, and if they are infectious to the vertebrate host, they will contribute to diminish the OspA vaccine efficacy even further. In clonal populations of *B. burgdorferi* which are allowed to grow *in vitro*, the prevalence of mutants that resist killing by anti-OspA antibody ranges between 10^{-5} and 10^{-2} [A. Sadziene *et al*, J. Exp. Med., 176:799-809 (1992)]. If such frequencies are reproduced in a feeding nymph, in which spirochete numbers may reach a mean of 7,848 within 15 hours of attachment [A. DeSilva *et al*, Am. J. Trop. Med. Hyg., 53:397-404 (1995)] then several mutants may be present in a single tick. Typical mutant phenotypes include those that express neither OspA nor OspB and, frequently, expressors of a chimeric molecule composed of an N-terminal fragment of OspA fused to a C-terminal fragment of OspB. These deletion mutants have been found in multiple strains of *B. burgdorferi* [P. Rosa *et al*, Mol. Microbiol., 6:3031-3040 (1992)] and in several tick isolates from California [T. Schwan *et al*, J. Clin. Microbiol., 31:3096-3108 (1993)]. Chimeric (deletion) mutants, which are able to resist killing with anti-OspA antibody alone, are killed by the combined action of antibody and complement. Since complement appears to be nonfunctional within the tick [T. Mather *et al*, cited above], and OspA, and probably its chimeric form as well, are not expressed within the vertebrate host shortly after infection, chimeric OspA escape mutants could infect the vertebrate host. Further, it is estimated that up to 2% of Ixodid ticks are only partially fed and are therefore still questing [Y. Lobet,

personal communication]. If such ticks have taken their incomplete meal from a *B. burgdorferi*-infected host, they will have spirochetes in their salivary glands which do not express OspA and which will readily infect an OspA-vaccinated host.

No booster effect has been observed [M. Philipp *et al*, cited above] nor should one be expected upon spirochetal challenge of an OspA-vaccinated host. Hence, the OspA vaccine may require repeated administrations to maintain effective antibody titers.

There is thus a need in the art for additional, and improved, methods and compositions for prevention of Lyme disease in humans and animals, and for treatment thereof.

Summary of the Invention

The present invention satisfies the need in the art by providing methods and compositions for prevention of Lyme Disease based on spirochetal antigens that are expressed by the spirochete during its residence in the vertebrate host. Such methods and compositions may also be employed for the treatment of Lyme Disease.

In one aspect, the invention provides an isolated *Borrelia burgdorferi* sensu lato surface antigen which is expressed *in vivo* by the spirochete in the vertebrate host. The antigen, referred to herein as P39.5, is further characterized as having a relative molecular mass of 39.5 kDa. Fragments of this antigen are also useful in the compositions and methods of this invention.

In another aspect, the invention provides novel *Borrelia* cassette string polypeptides/proteins.

In yet another aspect, the invention provides nucleic acid sequences encoding P39.5 or a fragment thereof, such as P7-1, as well as nucleic acid sequences encoding other *Borrelia* cassette string proteins or fragments thereof. These nucleic acid sequences include sequences which hybridizes to the above sequences under stringent conditions, allelic variants thereof and deletion mutants thereof.

In another aspect, the invention provides novel proteins comprising fragments of the P39.5 protein sequence or cassette string protein sequences

described above, optionally fused to, or mixed with, a second selected polypeptide or protein, which may be a protein of up to about 90% identity in its amino acid sequence with that of P39.5, or other *Borrelia* antigens, such as OspA, and proteins or polypeptides derived from other microorganisms.

5 In still another aspect, the invention provides novel protein compositions comprising the protein sequences of the antigen(s) described above, or fragments thereof, optionally mixed with a second selected polypeptide or protein, which may be a protein of up to about 90% identity in its amino acid sequence with that of P39.5, or other *Borrelia* antigens, such as OspA, and proteins or polypeptides
10 derived from other microorganisms.

In still a further aspect, the invention provides a method for recombinantly producing the above-described P39.5 protein, fragments thereof or fusion proteins containing such fragments, by expressing a DNA sequence encoding the protein, fragment or fusion protein in a selected host cell, and isolating the protein
15 therefrom. Host cells transformed with such DNA sequences are also provided herein.

In still another aspect, the invention provides an isolated antibody directed against the above-described P39.5 antigen, fragments thereof, cassette string proteins or fragments, or a fusion protein containing such fragments. These
20 antibodies may be polyclonal. The present invention also provides a method for producing such antibodies comprising immunizing a human or an animal with an isolated antigen as described above, or with one or a mixture of more than one fragment(s) thereof, or fusion protein containing one or more fragment(s) of this invention. Other types of antibodies may be prepared from such immunized animals,
25 e.g., recombinant, monoclonal, chimeric, humanized, etc.

In another aspect, the invention provides a therapeutic composition and methods for treating humans and/or animals with Lyme disease. The therapeutic composition contains an antibody, or protein, or fragment as described above and a suitable pharmaceutical carrier.

In a further aspect, the invention provides vaccine compositions and methods of vaccinating a human or animal patient against Lyme Disease by use of these above-described compositions. The compositions contain an effective amount of at least one *Borrelia* antigen of this invention, e.g., an antigen that is expressed *in vitro* by *Borrelia* spirochetes, said antigen having a relative molecular mass of 39,500 daltons, or antigenic fragment(s) thereof, or a fusion protein containing such a fragment, or cassette string protein(s), and a pharmaceutically acceptable carrier. The vaccine composition may contain the P39.5 protein, fragments thereof, fusion proteins or mixtures of proteins as described above.

10 In yet a further aspect, the invention provides vaccine compositions and methods of vaccinating a human or animal patient against Lyme Disease by use of nucleic acid compositions, e.g., DNA vaccines. The compositions contain an effective amount of a DNA sequence encoding at least one *Borrelia* antigen of this invention or antigenic fragment(s) thereof, cassette string antigen(s), or a fusion protein containing
15 such a fragment, and an optional pharmaceutically acceptable carrier.

In yet a further aspect, the invention provides a method for diagnosing Lyme borreliosis in a human or animal. This method includes the steps of incubating an antigen or antibody of this invention, preferably conventionally labeled for detection, with a sample of biological fluids from a human or an animal to be
20 diagnosed. In the presence of *B. burgdorferi* infection of the human or animal patient, an antigen-antibody complex is formed. Subsequently the reaction mixture is analyzed to determine the presence or absence of these antigen-antibody complexes. In a further embodiment, the diagnostic assay employs DNA sequences, preferably anti-sense sequences, of the antigen or fragments thereof, and diagnoses infection by the
25 presence of sequences in a biological fluid from the patient that hybridizes thereto. Other conventional assay formats may be employed using reagents identified by this invention.

In another aspect the invention provides a kit for diagnosing infection with *B. burgdorferi* in a human or an animal patient sample which contains at least
30 one antibody capable of binding at least one antigen of this invention of antigenic

fragment(s) thereof, or a DNA sequence encoding one or more antigen(s) of this invention or an anti-sense sequence thereof. The antibodies and sequences may be optionally labeled for detection, or a detection system may be included in the kit.

Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

Brief Description of the Drawings

Fig. 1 is a graph of the antibody dependent, complement-mediated killing (ADCK) titration of spirochetes from *B. burgdorferi* strains JD1 (○), B31 (Δ), and *B. garinii* strain IP90 (□) with serum from a rhesus monkey tick-inoculated with JD1 spirochetes.

Fig. 2 is a schematic depiction of portions of the DNA sequence of the novel P39.5 encoding a single open reading frame which encodes a deduced protein of 37.7 kDa. This DNA fragment is named 7-1, and the deduced protein referred to as P7-1. The region in black is a unique region spanning about bp769 to about bp854 of SEQ ID NO: 1. The region labeled IA spans about bp 1 to about bp 309 of SEQ ID NO: 1; IB spans about bp 855 to about bp 1189 of SEQ ID NO: 1). Regions IA and IB have a 70% identity. Regions IIA, which spans about bp 310 to about bp494 of SEQ ID NO: 1 and IIB, which spans about bp 595 to about bp 769 of SEQ ID NO: 1, have a 91% identity. Regions A, which spans about bp 208 to about bp 309 of SEQ ID NO: 1, and B, which spans about bp 495 to about bp 595 of SEQ ID NO: 1, have an 84% identity. Regions B and C, which together span about bp 1090 to about bp1189 of SEQ ID NO: 1, have a 90% identity.

Fig. 3 is a bar graph which illustrates *in vitro* killing of IP90 spirochetes with: plasma of a monkey infected with JD1 spirochetes and monkey complement (bar 1); antibody from the same plasma which is affinity purified on native P39.5 and monkey complement (bar 2); the same antibody as described for bar 2 without complement (bar 3); complement alone (bar 4); and BSK-H medium alone (bar 5). Error bars represent the standard deviation of the mean of two determinations.

Fig. 4 is a bar graph showing ADCK of spirochetes of the IP90 strain using: a plasma pool from monkeys infected with *B. burgdorferi* JD1 at a dilution of 1:10 (bars 1, 5); pooled serum from mice immunized with a recombinant form of P7-1 (rP7-1) and Ribi adjuvant at 1:10 (bars 2,6); and 1:50 (bar 3); and mice immunized with Ribi adjuvant alone (bars 4,7). Monkey complement was used in ADCK of bars 1-4 and guinea pig complement in ADCK of bars 5-7. Error bars represent the standard error of the mean of two determinations.

Fig. 5 is an illustration of the 'string' of silent VLS cassettes in a stretch of DNA about 8 kb in length, duplicated from J.R. Zhang *et al*, Cell, 89:275-285 (1997).

Fig. 6 is a Western blot of lysates from spirochetes of *B. burgdorferi* strains JD1 and B31, and *B. garinii* strain IP90 developed with serum from monkeys needle-inoculated (lanes 1) and tick-inoculated (lanes 2) with the JD1 spirochetes, and antibodies from the latter serum affinity purified off of whole live JD1 spirochetes (lanes 3).

Sequence Listing Designations

SEQ ID NO:1 is the nucleic acid sequence of clone 7-1.

SEQ ID NO:2 is the deduced protein sequence of clone 7-1.

SEQ ID NO:3 is the 5' end of the nucleic acid sequence of clone 1-1.

SEQ ID NO:4 is a partial nucleic acid sequence of clone 1-1, found in the middle of the nucleic acid sequence.

SEQ ID NO:5 is the 3' end of the nucleic acid sequence of clone 1-1.

SEQ ID NO:6 is the 5' end of the nucleic acid sequence of clone 3-1.

SEQ ID NO:7 is the 3' end of the nucleic acid sequence of clone 3-1.

SEQ ID NO:8 is the 5' end of the nucleic acid sequence of clone 6-1.

SEQ ID NO:9 is the 3' end of the nucleic acid sequence of clone 6-1.

SEQ ID NO:10 is the 5' end of the nucleic acid sequence of clone 9-1.

SEQ ID NO:11 is the 5' end of the nucleic acid sequence of clone

12-1.

SEQ ID NO:12 is the 3' end of the nucleic acid sequence of clone 12-1.

SEQ ID NO: 13 is a partial nucleic acid sequence obtained from clone 14 which, when added to the 5' terminus of clone 7-1 [SEQ ID NO: 1], forms a larger fragment of P39.5, i.e., P7-1. The first 5' terminal six bases are from the plasmid vector.

SEQ ID NO: 14 is the deduced protein sequence of SEQ ID NO: 13.

Detailed Description of the Invention

The present invention provides a novel *Borrelia* surface antigen, P39.5, that is expressed by the spirochete when it resides in the vertebrate host ("*in vivo*"). This antigen is targeted by antibody-dependent, complement-mediated (ADCK) killing *in vitro*. This novel antigen, fragments thereof, antibodies developed thereto, the nucleic acid sequences encoding same, and the use of such antigens, antibodies and nucleic acid sequences in diagnostic, therapeutic and prophylactic compositions and methods for the treatment or prevention of Lyme Disease provide advantages over the use of other *Borrelia* proteins and antibodies in known compositions and methods for this purpose.

I. The P39.5 Antigen of the Invention

In one embodiment, the present invention provides a novel isolated *Borrelia* antigen, referred to as P39.5. This antigen is expressed both *in vitro* and *in vivo* by *Borrelia* spirochetes, e.g., spirochetes of *B. garinii* strain IP90. This antigen, or a homolog thereof, is also expressed *in vivo* by spirochetes of the *B. burgdorferi sensu stricto* strains JD1, B31 and NT1. This antigen has an apparent molecular mass of 39.5 kDa in IP90 spirochetes, and is functionally characterized by the ability to elicit antibody in animals during the course of a natural infection with *Borrelia* spirochetes. These induced antibodies kill IP90 spirochetes by ADCK *in vitro*. The elicited antibody also kills spirochetes of the NT₁ strain of *B. burgdorferi sensu lato*, a strain isolated from the cerebrospinal fluid of a patient in the United States, but not

further characterized within the *sensu lato* complex of species. This strain was provided by Dr. Patricia Coyle, State University of New York at Stony Brook, New York.

The gene fragment designated 7-1 from a *B. burgdorferi sensu lato* strain (*B. garinii* strain IP90) inserted in pBluescript II plasmid was transformed in *E. coli* and deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland ("ATCC") on June 27, 1997 under Accession No. 98478. When this gene fragment is expressed in *E. coli*, isolated as a pure protein and the protein used as an immunogen in mice, the antibody thus produced reacts with P39.5 of IP90. Other gene fragments, designated, 1-1, 3-1, 6-1, 9-1 and 12-1, from *Borrelia garinii* strain IP90 were similarly each inserted in pBluescript II plasmids, transformed in *E. coli* and deposited. These latter deposits were made with the ATCC on or before June 25, 1998 under Accession Nos. _____ for 1-1, _____ for 3-1, _____ for 6-1, _____ for 9-1 and _____ for 12-1. All deposits were all made to meet the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure, and fully comply with the requirements of the United States Patent and Trademark Office for deposits for patent purposes. Sequences useful in the present invention may be obtained from these deposits.

A. Nucleic Acid Sequences

The present invention provides mammalian nucleic acid sequences encoding fragments of P39.5. The nucleic acid sequences of this invention are isolated from cellular materials with which they are naturally associated. As described in the examples below, a segment of 1190 bp which encodes a portion of the coding region of the *Borrelia* P39.5 gene was cloned and sequenced. It encompasses a single open reading frame that encodes a putative 37.7 kDa protein. This partial DNA sequence is reported in SEQ ID NOS: 13 and 1. SEQ ID NO: 13 is a sequence immediately 5' to the first base of SEQ ID NO: 1. Together these sequences from a partial protein of 1189 bp and about 396 amino acids. The sequenced fragment is composed of mostly hydrophilic domains that contain several

internally repeated regions and a unique region spanning about bp 627 to about bp 712 of SEQ ID NO: 1. See, Fig. 2, which identifies the repeated sequences and identifies the homologies and percent identities of such sequences.

Where in this text, protein and/or DNA sequences are defined by their percent homologies or identities to identified sequences, the algorithms used to calculate the percent identities or percent similarities include the following: the Smith-Waterman algorithm [J. F. Collins et al, 1988, Comput. Appl. Biosci., 4:67-72; J. F. Collins et al, Molecular Sequence Comparison and Alignment, (M. J. Bishop et al, eds.) In Practical Approach Series: Nucleic Acid and Protein Sequence Analysis XVIII, IRL Press: Oxford, England, UK (1987) pp.417], and the BLAST and FASTA programs [E. G. Shpaer et al, 1996, Genomics, 38:179-191]. These references are incorporated herein by reference.

Also encompassed within this invention are other *Borrelia* nucleic acid fragments, e.g., cassette string fragments, as well as fragments of P39.5. Such fragments are referred to as 1-1 (which encodes a protein/peptide P1-1), 3-1 (which encodes a protein/peptide P3-1), 6-1 (which encodes a protein/peptide P6-1), 9-1 (which encodes a protein/peptide P9-1) and 12-1 (which encodes a protein/peptide P12-1). Preferably, such fragments are characterized by encoding a biologically active portion of P39.5, e.g., an epitope. Generally, these oligonucleotide fragments are at least 15 nucleotides in length. However, oligonucleotide fragments of varying sizes may be selected as desired. Such fragments may be used for such purposes as performing polymerase chain reaction (PCR), e.g., on a biopsied tissue sample. For example, useful fragments of P39.5 DNA and corresponding sequences comprise sequences occurring between bp 793 -816 of SEQ ID NO: 1 and bp 59-85 of SEQ ID NO: 13. Other useful fragments are identified in Fig. 2. Fragments of 1-1 include sequences of SEQ ID NOS: 3, 4 and 5. Fragments of 3-1 include sequences of SEQ ID NOS: 6 and 7; fragments of 6-1 include sequences of SEQ ID NOS: 8 and 9. A fragment of 9-1 includes the sequence of SEQ ID NO: 10. Fragments of 12-1 include the sequences of SEQ ID NOS: 11 and 12. The complete sequences of 1-1, 3-1, 6-1, 9-1 and 12-1 and other useful fragments may be readily obtained by one of skill in the

art by resort to conventional DNA sequencing techniques applied to the DNA deposited with the ATCC above.

The DNA sequences of SEQ ID NOS: 1 and 3-12 as well as the deposited materials identified above permit one of skill in the art to readily obtain the corresponding anti-sense strands of these DNA sequences. Further, using known techniques, one of skill in the art can readily obtain additional genomic and cDNA sequences which flank the illustrated DNA sequences or the corresponding RNA sequences, as desired. Similarly the availability of SEQ ID NOS: 1 and 3-12 and the deposited materials of this invention permits one of skill in the art to obtain other species P39.5 analogs, *B. garinii* peptides, and fragments thereof, by use of the nucleic acid sequences of this invention as probes in a conventional technique, e.g., polymerase chain reaction. Allelic variants of these sequences within a species (i.e., sequences containing some individual nucleotide differences from a more commonly occurring sequence within a species, but which nevertheless encode the same protein or a protein with the same function) such as other variants of P39.5 SEQ ID NO: 2, may also be readily obtained given the knowledge of this sequence provided by this invention.

The present invention further encompasses nucleic acid sequences capable of hybridizing under stringent conditions [see, J. Sambrook et al, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory (1989)] to the sequences of SEQ ID NO: 1, their anti-sense strands, or biologically active fragments thereof. An example of a highly stringent hybridization condition is hybridization at 2XSSC at 65°C, followed by a washing in 0.1XSSC at 65°C for an hour. Alternatively, an exemplary highly stringent hybridization condition is in 50% formamide, 4XSSC at 42°C. Moderately high stringency conditions may also prove useful, e.g., hybridization in 4XSSC at 55°C, followed by washing in 0.1XSSC at 37°C for an hour. An alternative exemplary moderately high stringency hybridization condition is in 50% formamide, 4XSSC at 30°C.

According to the invention, the nucleic acid sequences may be modified. Utilizing the sequence data of SEQ ID NOS: 1 and 3-12, it is within the

skill of the art to obtain or prepare synthetically or recombinantly other polynucleotide sequences, or modified polynucleotide sequences, encoding the full-length proteins or useful fragments of the invention. Such modifications at the nucleic acid level include, for example, modifications to the nucleotide sequences which are silent or which
5 change the amino acids, e.g. to improve expression or secretion. Also included are allelic variations, caused by the natural degeneracy of the genetic code.

Also encompassed by the present invention are mutants of the P39.5 fragments and cassette string sequences 1-1, 3-1, 6-1, 7-1, 9-1 and 12-1 provided herein. Such mutants include amino terminal, carboxy terminal or internal
10 deletions, which substantially retain the antigenicity of the full-length P39.5 or other proteins or fragments. Such a truncated, or deletion, mutant may be expressed for the purpose of affecting the activity of the full-length or wild-type gene or gene fragments.

These nucleic acid sequences are useful for a variety of
15 diagnostic, prophylactic and therapeutic uses. Advantageously, the nucleic acid sequences are useful in the development of diagnostic probes and antisense probes for use in the detection and diagnosis of Lyme disease by utilizing a variety of known nucleic acid assays, e.g., Northern and Southern blots, polymerase chain reaction (PCR), and other assay techniques known to one of skill in the art. The nucleic acid
20 sequences of this invention are also useful in the production of P39.5 proteins and homologs as well as other proteins of *B. garinii*.

The nucleotide sequences of the invention may be isolated by conventional uses of polymerase chain reaction or cloning techniques such as those described in conventional texts such as Sambrook et al, cited above. For example, the
25 nucleic acid sequences of the antigen of this invention may be prepared or isolated from *B. garinii* DNA using DNA primers and probes and PCR techniques. Alternatively, the antigen may be obtained from gene banks derived from *B. garinii* whole genomic DNA. These sequences, fragments thereof, modifications thereto and the full-length sequences may be constructed recombinantly using conventional

genetic engineering or chemical synthesis techniques or PCR, and the like by utilizing the information provided herein.

B. Protein Sequences

The present invention also provides *B. burgdorferi* sensu lato proteins, such as *B. garinii* proteins and peptides, including P39.5 polypeptides or proteins, and the peptides/proteins represented by the designations P1-1, P3-1, P6-1, P7-1, P9-1 and P12-1 of this invention. These proteins are free from association with other contaminating proteins or materials with which they are found in nature. Because the native P39.5 was fully extracted into the detergent phase in a Triton-X114 extraction, it is likely a lipoprotein. The P39.5 antigen has a relative molecular mass of 39,500 daltons as measured by Western immunoblot (See Example 2 and Fig. 6). In one embodiment, the invention provides a partial P39.5 [SEQ ID NO:2] polypeptide of about 354 amino acids, likely a lipoprotein, having a predicted relative molecular mass of about 37.7 kD (i.e., "the P7-1 fragment"). This deduced amino acid sequence [SEQ ID NO: 2] is up to 22% identical to members of the variable major protein (Vmp) family of outer surface lipoproteins of *Borrelia hermsii* (see Example 6). It is about 50% identical to the Vmp-like sequence (vls) VlsE of the B31 strain of *B. burgdorferi* [J.-R. Zhang *et al*, cited above] and to other vls sequences of *B. burgdorferi* [i.e., Vls-6 Genbank no. U76406 (53% identity over 190 aa); VlsE Genbank no. U84553 (57% over 210 aa) and U84566 (58% over 209 aa) and U84555 (58% over 210 aa)].

VlsE is part of an antigen of *B. burgdorferi* that undergoes antigenic variation by a mechanism of recombination whereby a central fragment of the expressed copy (VlsE) is recombined with fragments from a string of 15 "cassettes" located upstream from the expressed copy [J. Zhang, cited above]. Each cassette is on average 500 bp in length, and the whole string occupies a stretch of DNA of about 8kb. One of the remarkable features of this string of cassettes is that in *B. burgdorferi* B31, the cassettes are arranged in a nearly contiguous open reading frame interrupted only by a stop codon in cassette vls11 and two frame shifts in

cassettes vls14 and vls16. See, e.g., Fig. 6, which is a copy of a similar structure defined in Zhang et al, cited above.

A longer partial protein sequence of P39.5 is formed by the direct fusion of the partial sequence from clone 14 [SEQ ID NO: 14] to the 5' end of the sequence of SEQ ID NO: 2. The identification of the sequence from clone 14 as a
5 the sequence 5' to the sequence of P7-1 resulting from overlapping sequences between the two clones from which these sequences were obtained, which overlapping sequences demonstrated that they were part of the same open reading frame. Thus the Leu (amino acid 47 of SEQ ID NO: 14) is immediately followed by the Lys
10 (amino acid 1 of SEQ ID NO: 2) in the larger P39.5 deduced amino acid sequence.

The present invention provides partial DNA and deduced amino acid sequences of several fragments which appear to be part of the cassette string of *B. garinii* IP90. These fragments, which may include 7-1, are named 1-1, 3-1, 6-1, 9-1, and 12-1, and are between 1 and 2 kb in length. Each of them expresses a
15 peptide (off of the lacZ promoter of pBluescript) which is commensurate with the size of the insert and which reacts with antibody from infected monkeys. None of the 5' ends of these fragments [SEQ ID NOS: 1, 3, 6, 8, 10 and 11] contains a hydrophobic leader or a signal peptidase II consensus sequence of the type that is characteristic of bacterial lipoproteins. These fragments must therefore be part of the cassette string of
20 IP90 and, like the cassette string of B31, they are in-frame. These vls-like proteins are identified by partial 5' and 3' sequences [see, e.g., SEQ ID NOS: 1, 3, 5 through 12]. One of skill in the art using conventional techniques, such as PCR, may readily use the partial 5' and 3' sequences provided herein and the DNA sequences of (or DNA library of) *B. garinii* or the materials deposited with the ATCC for each cassette
25 string protein identified above, to identify the complete sequences thereof. Such methods are routine and not considered to require undue experimentation, given the information provided herein.

Antigens of this invention may be characterized by immunological measurements including, without limitation, western blot,
30 macromolecular mass determinations by biophysical determinations, such as SDS-

PAGE/staining, HPLC and the like, antibody recognition assays, T-cell recognition assays, MHC binding assays, and assays to infer immune protection or immune pathology by adoptive transfer of cells, proteins or antibodies.

5 The proteinaceous P39.5 surface antigen of this invention (as well as its naturally occurring variants or analogs in other species of *Borrelia* or the other Vls-like proteins identified herein) may be isolated in the form of a complete intact protein, or a polypeptide or fragment thereof. In one embodiment, P39.5 is isolated by immunoblot procedures according to its respective molecular mass, as described below in Example 5. Such isolation provides the antigen in a form

10 substantially free from other proteinaceous and non-proteinaceous materials of the microorganism and the tick vector. The molecules comprising the *Borrelia* polypeptides and antigens of this invention may be isolated from the spirochete and further purified using any of a variety of conventional methods including: liquid chromatography such as normal or reversed phase, using HPLC, FPLC and the like;

15 affinity chromatography (such as with inorganic ligands or monoclonal antibodies); size exclusion chromatography; immobilized metal chelate chromatography; gel electrophoresis; and the like. One of skill in the art may select the most appropriate isolation and purification techniques without departing from the scope of this invention.

20 Alternatively, the amino acid sequences of P39.5 or the other *Borrelia* proteins of this invention may be produced recombinantly following conventional genetic engineering techniques [see e.g., Sambrook et al, cited above and the detailed description of making the proteins below].

i. Analogs/Modified Antigens

25 Also included in the invention are analogs, or modified versions, of the P39.5 protein or vls-like proteins P1-1, P3-1, P6-1, P7-1, P9-1 and P12-1, provided herein. Typically, such analogs differ from the specifically identified proteins by only one to four codon changes. Examples include polypeptides with minor amino acid variations from the illustrated partial amino acid sequence of, for

30 example, P7-1 (SEQ ID NO: 2), in particular, conservative amino acid replacements.

Conservative replacements are those that take place within a family of amino acids that are related in their side chains and chemical properties. Also provided are homologs of the proteins of the invention which are characterized by having at least 85% identity with SEQ ID NO:2 or with the sequences of the vls-like proteins. Based on the sequence information provided herein, one of skill in the art can readily obtain full-length P7-1 or P7-1 homologs and analogs, as well as the full-length vls-like 1-1, 3-1, 6-1, 9-1 and 12-1 protein homologs and analogs from other bacterial species.

An antigen of the present invention may also be modified to increase its immunogenicity. For example, the antigen may be coupled to chemical compounds or immunogenic carriers, provided that the coupling does not interfere with the desired biological activity of either the antigen or the carrier. For a review of some general considerations in coupling strategies, see Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, ed. E. Harlow and D. Lane (1988). Useful immunogenic carriers known in the art, include, without limitation, keyhole limpet hemocyanin (KLH); bovine serum albumin (BSA), ovalbumin, PPD (purified protein derivative of tuberculin); red blood cells; tetanus toxoid; cholera toxoid; agarose beads; activated carbon; or bentonite. Useful chemical compounds for coupling include, without limitation, dinitrophenol groups and arsonilic acid.

The antigen may also be modified by other techniques, such as denaturation with heat and/or SDS.

ii. *Fragments/Deletion Mutants*

Further encompassed by this invention are additional fragments of the P39.5 polypeptide, the P7-1 peptide or of the other vls-like proteins identified herein. Such fragments are desirably characterized by having a biological activity similar to that displayed by the complete protein, including, e.g., the ability to induce antibodies to the causative agent of Lyme Disease. These fragments may be designed or obtained in any desired length, including as small as about 5-8 amino acids in length. Such a fragment may represent an epitope of the protein.

The internal repeats of P39.5 (see Fig. 2) indicate that this protein, like OspA, may undergo homologous recombinations in *Borrelia* which

may lead to mutants expressing shortened, partially-deleted versions of the gene. Thus, the P7-1 protein [SEQ ID NO:2] of the invention may be modified to create deletion mutants, for example, by truncation at the amino or carboxy termini, or by elimination of one or more amino acids. Deletion mutants of P7-1 created by
5 homologous recombination of its repeat sequences (Fig. 2) are also encompassed by this invention, as are the DNA sequences encoding them. In certain deletion mutants, portions of the P39.5 coding region, described above, e.g., regions IIA, IIB, and B, are deleted.

Deletion mutants of the P39.5 antigens that, like P39.5
10 and unlike OspA, are expressed *in vivo*, will likely be killed upon infection of the vertebrate host. Most OspA deletion mutants escape killing with anti-OspA antibody in the absence of complement, but are killed by this antibody and complement acting together. Since anti-OspA antibody kills spirochetes in the tick midgut (where OspA is expressed, but complement is likely not active), OspA deletion mutants may escape
15 the anti-Osp A antibody elicited by the OspA vaccine. In contrast, since P39.5 is expressed *in vivo*, where complement and anti-P39.5 antibody are both present, P39.5 deletion mutants may not escape a P39.5 based vaccine.

Still other modified fragments of P39.5, P1-1, P3-1, P6-1, P7-1, P9-1, or P12-1 may be prepared by any number of now conventional
20 techniques to improve production thereof, to enhance protein stability or other characteristics, e.g. binding activity or bioavailability, or to confer some other desired property upon the protein. Other useful fragments of these polypeptides may be readily prepared by one of skill in the art using known techniques, such as deletion mutagenesis and expression.

25 *iii. Fusion or Multimeric Proteins and Compositions*

The P39.5 protein of the present invention, or fragments of it, as well as the vls-like cassette string proteins or fragments thereof, may also be constructed, using conventional genetic engineering techniques as part of a larger and/or multimeric protein or protein compositions. Antigens of this invention
30 may be in combination with *B. burgdorferi* outer surface proteins, such as OspA,

OspB, OspC, as well as BmpA, B, C, or various fragments of the antigens described herein may be in combination with each other. In such combination, the antigen may be in the form of a fusion protein. The antigen of the invention may be optionally fused to a selected polypeptide or protein, e.g. *Borrelia* antigens OspA, OspB, OspC, BmpA, BmpB, BmpC, other *Borrelia* antigens, and proteins or polypeptides derived from other microorganisms. For example, an antigen or polypeptide of this invention may be fused at its N-terminus or C-terminus to OspA polypeptide, or OspB polypeptide or OspC polypeptide or to a non-OspA non-OspB polypeptide or combinations thereof. OspA and OspB polypeptides which may be useful for this purpose include polypeptides identified by the prior art [see, e.g. PCT/US91/04056] and variants thereof. Non-OspA, non-OspB polypeptides which may be useful for this purpose include polypeptides of the invention and those identified by the prior art, including, the *B. burgdorferi* OspC protein, the flagella-associated protein and fragments thereof, other *B. burgdorferi* proteins and fragments thereof, and non-*B. burgdorferi* proteins and fragments thereof.

Still another fusion protein of this invention is provided by expressing the DNA molecule formed by the P39.5 DNA sequence or a fragment thereof fused to DNA fragments that are homologous (25-95% identity) to P39.5. One example of such a protein comprises the amino acid sequence of SEQ ID NO: 2 to which is fused amino acid fragments that are up to 95% identical to that sequence. These fragments may be inserted in any order and may contain repeated sequences such as those depicted in Fig. 2. These long strings of DNA that form a single open reading frame may be constructed from P39.5 homologs, including P39.5, or be derived from the naturally occurring long open reading frames, such as one or more of the vls cassette proteins. The vls cassette proteins from *B. garinii* (e.g., the proteins designated P1-1, P3-1, P6-1, P9-1 and/or P12-1) may be fused to each other and/or inserted into the P39.5 or P7-1 DNA sequence, thereby creating a large DNA molecule which expresses a protein which may stimulate a variety of antibody specificities.

These fusion proteins comprising multiple polypeptides of this invention are constructed for use in the methods and compositions of this invention. These fusion proteins or multimeric proteins may be produced recombinantly, or may be synthesized chemically. They also may include the polypeptides of this invention fused or coupled to moieties other than amino acids, including lipids and carbohydrates. Further, antigens of this invention may be employed in combination with other *Borrelia* vaccinal agents described by the prior art, as well as with other species of vaccinal agents derived from other viruses. Such proteins are effective in the prevention, treatment and diagnosis of Lyme disease as caused by a wide spectrum of *B. burgdorferi* isolates.

A protein composition which may be a preferred alternative to the fusion proteins described above is a cocktail (i.e., a simple mixture) containing different P39.5 protein or fragments, or different mixtures of the cassette string proteins of this invention. Such mixtures of these proteins or antigenic fragments thereof are likely to be useful in the generation of desired antibodies to *B. garinii*.

iv. Salts

An antigen of the present invention may also be used in the form of a pharmaceutically acceptable salt. Suitable acids and bases which are capable of forming salts with the polypeptides of the present invention are well known to those of skill in the art, and include inorganic and organic acids and bases.

II. Methods of Making Antigens and Nucleic Acid Sequences of the Invention

A. Expression In Vitro

To produce recombinant P7-1 and/or other cassette string proteins or other fragments of P39.5 of this invention, the DNA sequences of the invention are inserted into a suitable expression system. Desirably, a recombinant molecule or vector is constructed in which the polynucleotide sequence encoding the selected protein, e.g., P7-1, is operably linked to a heterologous expression control

sequence permitting expression of the protein. Numerous types of appropriate expression vectors are known in the art for protein expression, by standard molecular biology techniques. Such vectors are selected from among conventional vector types including insects, e.g., baculovirus expression, or yeast, fungal, bacterial or viral expression systems. Other appropriate expression vectors, of which numerous types are known in the art, can also be used for this purpose. Methods for obtaining such expression vectors are well-known. See, Sambrook et al, Molecular Cloning. A Laboratory Manual, 2d edition, Cold Spring Harbor Laboratory, New York (1989); Miller et al, Genetic Engineering, 8:277-298 (Plenum Press 1986) and references cited therein.

Suitable host cells or cell lines for transfection by this method include bacterial cells. Preferably, at least for use of the P39.5 protein which is believed to be a lipoprotein (e.g., see Example 5), the selected protein is expressed in bacteria, which have the cellular machinery to attach lipids. This expression system is especially preferred where the protein is being expressed for use as a vaccine or therapeutic. For example, the various strains of *E. coli* (e.g., HB101, MC1061, and strains used in the following examples) are well-known as host cells in the field of biotechnology. Various strains of *B. subtilis*, *Pseudomonas*, *Streptomyces*, and other bacilli and the like are also be employed in this method.

Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention. Other fungal cells may also be employed as expression systems. Although yeast can also lipidate proteins, the lipidation pattern may be different from bacteria, i.e., different from the native protein.

Mammalian cells, such as human 293 cells, Chinese hamster ovary cells (CHO), the monkey COS-1 cell line or murine 3T3 cells derived from Swiss, Balb-c or NIH mice are used. Another suitable mammalian cell line is the CV-1 cell line. Still other suitable mammalian host cells, as well as methods for transfection, culture, amplification, screening, production, and purification are known in the art. [See, e.g., Gething and Sambrook, Nature, 293:620-625 (1981), or

alternatively, Kaufman et al, Mol. Cell. Biol., 5(7):1750-1759 (1985) or Howley et al, U. S. Patent 4,419,446].

Alternatively, insect cells such as *Spodoptera frugiperda* (Sf9) cells may be used.

5 Thus, the present invention provides a method for producing a recombinant *Borrelia* protein, e.g., P7-1 or other cassette string proteins, which involves transfecting, e.g., by conventional means such as electroporation, a host cell with at least one expression vector containing a polynucleotide of the invention under the control of a transcriptional regulatory sequence. The transfected or transformed
10 host cell is then cultured under conditions that allow expression of the protein. The expressed protein is recovered, isolated, and optionally purified from the cell (or from the culture medium, if expressed extracellularly) by appropriate means known to one of skill in the art.

For example, the proteins are isolated in soluble form following
15 cell lysis, or extracted using known techniques, e.g., in guanidine chloride. If desired, the proteins or fragments of the invention are produced as a fusion protein. Such fusion proteins are those described above. Alternatively, for example, it may be desirable to produce fusion proteins to enhance expression of the protein in a selected host cell, to improve purification, or for use in monitoring the presence of the desired
20 protein, e.g., P7-1, in tissues, cells or cell extracts. Suitable fusion partners for the proteins of the invention are well known to those of skill in the art and include, among others, β -galactosidase, glutathione-S-transferase, and poly-histidine.

B. *Expression In Vivo*

Alternatively, where it is desired that the P7-1 or other cassette
25 string protein of the invention (whether full-length or a desirable fragment) be expressed *in vivo*, e.g., to induce antibodies, or as a DNA vaccine, an appropriate vector for delivery is readily selected by one of skill in the art. Exemplary vectors for *in vivo* gene delivery are readily available from a variety of academic and commercial sources, and include, e.g., adeno-associated virus [International patent application No.
30 PCT/US91/03440], adenovirus vectors [M. Kay et al, Proc. Natl. Acad. Sci. USA,

91:2353 (1994); S. Ishibashi et al, J. Clin. Invest., 92:883 (1993)], or other viral vectors, e.g., various poxviruses, vaccinia, etc. Methods for insertion of a desired gene, e.g., P7-1, and obtaining *in vivo* expression of the encoded protein, are well known to those of skill in the art.

5 III. Antibodies of the Invention

 The present invention also provides antibodies capable of recognizing and binding the isolated, or modified, or multimeric antigens of this invention, including antibodies derived from mixtures of such antigens or fragments thereof. These antibodies are useful in diagnosis of Lyme disease and in therapeutic
10 compositions for treating humans and/or animals that test positive for, or, prior to testing, exhibit symptoms of, Lyme Disease. The antibodies are useful in diagnosis alone or in combination with antibodies to other antigens of this invention as well as antibodies to other known *B. burgdorferi* antigens. These antibodies are also useful in passive vaccine compositions.

15 The antibodies of this invention are generated by conventional means utilizing the isolated, recombinant or modified antigens of this invention, or mixtures of such antigens or antigenic fragments. For example, polyclonal antibodies are generated by conventionally stimulating the immune system of a selected animal or human with the isolated antigen or mixture of antigenic proteins or peptides of this
20 invention, allowing the immune system to produce natural antibodies thereto, and collecting these antibodies from the animal or human's blood or other biological fluid.

 For example, an antibody according to the invention is produced by administering to a vertebrate host the antigen or antigenic composition of this invention, e.g., P7-1. Preferably a recombinant version of P7-1 (rP7-1) is used as an
25 immunogen. A suitable polyclonal antibody against the P7-1 antigen kills IP90 spirochetes *in vitro* by antibody-dependent, complement-mediated killing (ADCK) regardless of whether the antibody was obtained by: (1) affinity purification using as immunoabsorbant native P39.5 antigen of IP90 spirochetes (as separated on a Western blot; see Fig. 6) and as source of antibody the antiserum generated during an

infection of rhesus monkeys with JD1 spirochetes or, (2) by immunizing mice with recombinant P7-1 from IP90 (rP7-1).

Thus, an antibody of the invention is isolated by affinity purifying antiserum generated during an infection of a vertebrate animal, e.g., a rhesus monkey, with JD1 spirochetes, using as immunoabsorbant the native P39.5 antigen of IP90, or one or more of the cassette string proteins identified herein. Similarly, an antibody of the invention is isolated by immunizing mice with a purified, recombinant antigen of this invention, or a purified, isolated P39.5 of native origin. Monoclonal antibodies (MAbs) directed against P39.5 are also generated. Hybridoma cell lines expressing desirable MAbs are generated by well-known conventional techniques, e.g. Kohler and Milstein and the many known modifications thereof. Similarly desirable high titer antibodies are generated by applying known recombinant techniques to the monoclonal or polyclonal antibodies developed to these antigens [see, e.g., PCT Patent Application No. PCT/GB85/00392; British Patent Application Publication No. GB2188638A; Amit et al., Science, 233:747-753 (1986); Queen et al., Proc. Nat'l. Acad. Sci. USA, 86:10029-10033 (1989); PCT Patent Application No. PCT/WO9007861; and Riechmann et al., Nature, 332:323-327 (1988); Huse et al., Science, 246:1275-1281 (1988)a].

Given the disclosure contained herein, one of skill in the art may generate chimeric, humanized or fully human antibodies directed against P39.5 or the cassette proteins, or antigenic fragments thereof by resort to known techniques by manipulating the complementarity determining regions of animals or human antibodies to the antigen of this invention. See, e.g., E. Mark and Padlin, "Humanization of Monoclonal Antibodies", Chapter 4, The Handbook of Experimental Pharmacology, Vol. 113, The Pharmacology of Monoclonal Antibodies, Springer-Verlag (June, 1994).

Alternatively, the antigens are assembled as multi-antigenic complexes [see, e.g., European Patent Application 0339695, published November 2, 1989] or as simple mixtures of antigenic proteins/peptides and employed to elicit high titer

antibodies capable of binding the selected antigen(s) as it appears in the biological fluids of an infected animal or human.

Further provided by the present invention are anti-idiotypic antibodies (Ab2) and anti-anti-idiotypic antibodies (Ab3). Ab2 are specific for the target to which anti-P39.5 antibodies of the invention bind and Ab3 are similar to P39.5 antibodies (Ab1) in their binding specificities and biological activities [see, e.g., M. Wettendorff et al., "Modulation of anti-tumor immunity by anti-idiotypic antibodies." In Idiotypic Network and Diseases, ed. by J. Cerny and J. Hiernaux J, Am. Soc. Microbiol., Washington DC: pp. 203-229, (1990)]. These anti-idiotypic and anti-anti-idiotypic antibodies are produced using techniques well known to those of skill in the art. Such anti-idiotypic antibodies (Ab2) can bear the internal image of P39.5, the cassette proteins, or fragments thereof and are thus useful for the same purposes as P39.5, the cassette proteins or the fragments.

In general, polyclonal antisera, monoclonal antibodies and other antibodies which bind to the selected antigen (Ab1) are useful to identify epitopes of P39.5 or the cassette proteins to separate P39.5 (or the cassette proteins) and analogs thereof from contaminants in living tissue (e.g., in chromatographic columns and the like), and in general as research tools and as starting material essential for the development of other types of antibodies described above. Anti-idiotypic antibodies (Ab2) are useful for binding the same target and thus may be used in place of the original antigen, e.g., P39.5, to induce an immune response. The Ab3 antibodies are useful for the same reason the Ab1 are useful. Other uses as research tools and as components for separation of P39.5 or the cassette proteins, from other contaminants, for example, are also contemplated for the above-described antibodies.

For use in diagnostic assays, the antibodies are associated with conventional labels which are capable, alone or in concert with other compositions or compounds, of providing a detectable signal. Where more than one antibody is employed in a diagnostic method, the labels are desirably interactive to produce a detectable signal. Most desirably, the label is detectable visually, e.g. colorimetrically. A variety of enzyme systems have been described in the art which will operate to

reveal a colorimetric signal in an assay. As one example, glucose oxidase (which uses glucose as a substrate) releases peroxide as a product. Peroxidase, which reacts with peroxide and a hydrogen donor such as tetramethyl benzidine (TMB) produces an oxidized TMB that is seen as a blue color. Other examples include horseradish
5 peroxidase (HRP) or alkaline phosphatase (AP), and hexokinase in conjunction with glucose-6-phosphate dehydrogenase which reacts with ATP, glucose, and NAD⁺ to yield, among other products, NADH that is detected as increased absorbance at 340 nm wavelength. Other label systems that may be utilized in the methods of this invention are detectable by other means, e.g., colored latex microparticles [Bangs
10 Laboratories, Indiana] in which a dye is embedded may be used in place of enzymes to form conjugates with the antibodies and provide a visual signal indicative of the presence of the resulting complex in applicable assays. Still other labels include fluorescent compounds, radioactive compounds or elements. Detectable labels for attachment to antibodies useful in diagnostic assays of this invention may be easily
15 selected from among numerous compositions known and readily available to one skilled in the art of diagnostic assays. The methods and antibodies of this invention are not limited by the particular detectable label or label system employed.

IV. Diagnostic Methods and Assays

The present invention also provides methods of diagnosing Lyme
20 disease. These diagnostic methods are useful for diagnosing humans or animals exhibiting the clinical symptoms of, or suspected of having, Lyme disease.

In one embodiment, this diagnostic method involves detecting the presence of naturally occurring anti-P39.5 antibodies which are produced by the infected human or animal patient's immune system in its biological fluids, and which
25 are capable of binding to the antigens of this invention or combinations thereof. This method comprises the steps of incubating a P39.5 antigen or a cassette string antigen of this invention with a sample of biological fluids from the patient. Antibodies present in the fluids as a result of *B. burgdorferi* infection will form an antibody-antigen complex with the antigen. Subsequently the reaction mixture is analyzed to

determine the presence or absence of these antigen-antibody complexes. The step of analyzing the reaction mixture comprises contacting the reaction mixture with a labeled specific binding partner for the antibody.

5 In a similar embodiment, this diagnostic method involves detecting the presence of naturally occurring anti-P1-1, anti-P3-1, anti-P6-1, anti P7-1, anti-P9-1, and/or anti-P12-1 antibodies which are produced by the infected human or animal patient's immune system in its biological fluids, and which are capable of binding to the antigens of this invention or combinations thereof. This method comprises the steps of incubating a one or preferably, a mixture, of these antigen(s) of this invention
10 with a sample of biological fluids from the patient. Antibodies present in the fluids as a result of *B. burgdorferi* infection will form antibody-antigen complexes with the antigen(s). Subsequently the reaction mixture is analyzed to determine the presence or absence of these antigen-antibody complexes. The step of analyzing the reaction mixture comprises contacting the reaction mixture with a labeled specific binding
15 partner for the antibody.

In one embodiment of the method, purified antigen, fragment or mixture of antigens is electro- or dot-blotted onto nitrocellulose paper. Subsequently, the biological fluid (e.g. serum or plasma) is incubated with the blotted antigen, and antibody in the biological fluid is allowed to bind to the antigen(s). The bound
20 antibody is then detected by standard immunoenzymatic methods.

In another embodiment of the method, latex beads are conjugated to the antigen(s) of this invention. Subsequently, the biological fluid is incubated with the bead/protein conjugate, thereby forming a reaction mixture. The reaction mixture is then analyzed to determine the presence of the antibodies.

25 In another embodiment, the diagnostic method of the invention involves detecting the presence of the naturally occurring P39.5 or cassette string antigen(s) itself in its association with the *Borrelia* pathogen in the biological fluids of an animal or human infected by the pathogen. This method includes the steps of incubating an antibody of this invention (e.g. produced by administering to a suitable
30 human and/or animal an antigen of this invention preferably conventionally labelled for

detection) with a sample of biological fluids from a human or an animal to be diagnosed. In the presence of *Borrelia* infection of the human or animal patient, an antigen-antibody complex is formed (specific binding occurs). Subsequently, excess labeled antibody is optionally removed, and the reaction mixture is analyzed to
5 determine the presence or absence of the antigen-antibody complex and the amount of label associated therewith.

Assays employing a protein antigen of the invention can be heterogenous (i.e., requiring a separation step) or homogenous. If the assay is heterogenous, a variety of separation means can be employed, including
10 centrifugation, filtration, chromatography, or magnetism.

One preferred assay for the screening of blood products or other physiological or biological fluids is an enzyme linked immunosorbant assay, i.e., an ELISA. Typically in an ELISA, the isolated antigen(s) of the invention is adsorbed to the surface of a microtiter well directly or through a capture matrix (i.e., antibody).
15 Residual protein-binding sites on the surface are then blocked with an appropriate agent, such as bovine serum albumin (BSA), heat-inactivated normal goat serum (NGS), or BLOTTO (a buffered solution of nonfat dry milk which also contains a preservative, salts, and an antifoaming agent). The well is then incubated with a biological sample suspected of containing specific anti-*B. burgdorferi* antibody. The
20 sample can be applied neat, or more often, it can be diluted, usually in a buffered solution which contains a small amount (0.1-5.0% by weight) of protein, such as BSA, NGS, or BLOTTO. After incubating for a sufficient length of time to allow specific binding to occur, the well is washed to remove unbound protein and then incubated with labeled anti-human immunoglobulin (α HuIg) or labeled antibodies to
25 other species, e.g., dogs. The label can be chosen from a variety of enzymes, including horseradish peroxidase (HRP), β -galactosidase, alkaline phosphatase, and glucose oxidase, as described above. Sufficient time is allowed for specific binding to occur again, then the well is washed again to remove unbound conjugate, and the substrate for the enzyme is added. Color is allowed to develop and the optical density
30 of the contents of the well is determined visually or instrumentally.

Further, MABs or other antibodies of this invention which are capable of binding to the antigen(s) can be bound to ELISA plates. In another diagnostic method, the biological fluid is incubated on the antibody-bound plate and washed. Detection of any antigen-antibody complex, and qualitative measurement of the labeled MAb is performed conventionally, as described above.

Other useful assay formats include the filter cup and dipstick. In the former assay, an antibody of this invention is fixed to a sintered glass filter to the opening of a small cap. The biological fluid or sample (5 mL) is worked through the filter. If the antigen is present (i.e., *B. burgdorferi* infection), it will bind to the filter which is then visualized through a second antibody/detector. The dipstick assay involves fixing an antigen or antibody to a filter, which is then dipped in the biological fluid, dried and screened with a detector molecule.

Other diagnostic assays can employ the antigen(s) or fragments of this invention as nucleic acid probes or an anti-sense sequences, which can identify the presence of infection in the biological fluid by hybridizing to complementary sequences produced by the pathogen in the biological fluids. Such techniques, such as PCR, Northern or Southern hybridizations etc. are well known in the art.

It should be understood by one of skill in the art that any number of conventional protein assay formats, particularly immunoassay formats, or nucleic acid assay formats, may be designed to utilize the isolated antigens and antibodies or their nucleic acid sequences or anti-sense sequences of this invention for the detection of *Borrelia* infection in animals and humans. This invention is thus not limited by the selection of the particular assay format, and is believed to encompass assay formats which are known to those of skill in the art.

V. Diagnostic Kits

For convenience, reagents for ELISA or other assays according to this invention may be provided in the form of kits. Such kits are useful for diagnosing infection with *Borrelia* in a human or an animal sample. Such a diagnostic kit contains an antigen of this invention and/or at least one antibody capable of binding an antigen of this invention, or the nucleic acid sequences encoding them, or their anti-

sense sequences. Alternatively, such kits may contain a simple mixture of such antigens or sequences, or means for preparing a simple mixture.

These kits can include microtiter plates to which the *Borrelia* antigen proteins or antibodies or nucleic acid sequences of the invention have been pre-
5 adsorbed, various diluents and buffers, labeled conjugates for the detection of specifically bound antigens or antibodies, or nucleic acids and other signal-generating reagents, such as enzyme substrates, cofactors and chromogens. Other components of these kits can easily be determined by one of skill in the art. Such components may include polyclonal or monoclonal capture antibodies, antigen of this invention, or a
10 cocktail of two or more of the antibodies, purified or semi-purified extracts of these antigens as standards, MAb detector antibodies, an anti-mouse or anti-human antibody with indicator molecule conjugated thereto, an ELISA plate prepared for absorption, indicator charts for colorimetric comparisons, disposable gloves, decontamination instructions, applicator sticks or containers, and a sample preparator
15 cup. Such kits provide a convenient, efficient way for a clinical laboratory to diagnose *Borrelia* infection.

VI. Therapeutic Compositions

The antigens, antibodies, nucleic acid sequences or anti-sense sequences of the invention, alone or in combination with other antigens, antibodies,
20 nucleic acid sequences or anti-sense sequences may further be used in therapeutic compositions and in methods for treating humans and/or animals with Lyme Disease. For example, one such therapeutic composition may be formulated to contain a carrier or diluent and one or more of the anti-P7-1 or other anti-cassette string protein antibodies of the invention. Suitable pharmaceutically acceptable carriers facilitate
25 administration of the proteins but are physiologically inert and/or nonharmful.

Carriers may be selected by one of skill in the art. Exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, olive oil, sesame oil, and water. Additionally, the carrier or diluent

may include a time delay material, such as glycerol monostearate or glycerol distearate alone or with a wax. In addition, slow release polymer formulations can be used.

Optionally, this composition may also contain conventional pharmaceutical ingredients, such as preservatives, or chemical stabilizers. Suitable ingredients which may be used in a therapeutic composition in conjunction with the antibodies include, for example, casamino acids, sucrose, gelatin, phenol red, N-Z amine, monopotassium diphosphate, lactose, lactalbumin hydrolysate, and dried milk.

Alternatively, or in addition to the antibodies of the invention, other agents useful in treating Lyme disease, e.g., antibiotics or immunostimulatory agents and cytokine regulation elements, are expected to be useful in reducing or eliminating disease symptoms. Agents which can be used to suppress or counteract the immune suppressants released by the tick vector or the spirochete should act to assist the natural immunity of the infected human or animal. Thus, such agents may operate in concert with the therapeutic compositions of this invention. The development of therapeutic compositions containing these agents is within the skill of one in the art in view of the teachings of this invention.

According to the method of the invention, a human or an animal may be treated for Lyme Disease by administering an effective amount of such a therapeutic composition. An "effective amount" may be between about 0.05 to about 1000 $\mu\text{g/mL}$ of an antibody of the invention. A suitable dosage may be about 1.0 mL of such an effective amount. Such a composition may be administered 1 - 3 times per day over a 1 day to 12 week period. However, suitable dosage adjustments may be made by the attending physician or veterinarian depending upon the age, sex, weight and general health of the human or animal patient. Preferably, such a composition is administered parenterally, preferably intramuscularly or subcutaneously. However, it may also be formulated to be administered by any other suitable route, including orally or topically.

VII. Vaccine Compositions

None of the potential problems of the prior art arise with a vaccine based on an antigen which is expressed in the vertebrate host. An improved surface-antigen-based vaccine for the prevention of Lyme disease in humans and other animals is provided by the inclusion of the P39.5 antigen of this invention, and a pharmaceutically acceptable carrier or diluent. This vaccine composition may contain one or more of the isolated, recombinant, modified or multimeric forms of the P39.5 antigen of the invention, or mixtures thereof. Similarly, salts of the antigenic proteins may be employed in such compositions.

Another embodiment of a composition of the present invention is based on the other cassette string antigens, i.e., P1-1, P3-1, P6-1, P7-1, P9-1 and P12-1. The inventor proposes that the mechanism of antigenic variation to which the vlsE antigen is subjected indicates that this antigen is crucially important for spirochetal survival in the vertebrate host. According to this invention, a novel vaccine method involves circumventing the spirochetal defense mechanism by immunizing a host with a large fraction of the epitopes that are expressed on the cassette string that is the very source of the variation. This is made possible by the unique fact that most of this cassette string is in frame. The inventors have demonstrated this concept, as described in the Examples below, by immunizing a host with the cassette string antigen, P7-1, and inducing antibody that kills the spirochetes. Thus, according to this invention, one method of vaccination thus involves administering to the host several or all of the cloned and purified proteins described above, which are derived from antigenically dissimilar sections of the IP90 cassette string. While a variety of immunogenic compositions may be prepared from such proteins, it is presently preferred that a simple mixture of two or more of the cassette string proteins or peptide fragments thereof be employed for this purpose.

Combinations of the antigen(s) of this invention with other antigens of *B. burgdorferi*, such as the OspA, OspB and OspC proteins, BmpA, B, C or D proteins, or fragments thereof are also encompassed by this invention.

Exemplary carriers are as described above for therapeutic compositions. Optionally, the vaccine composition may further contain adjuvants, preservatives, chemical stabilizers, or other antigenic proteins. Typically, stabilizers, adjuvants, and preservatives are optimized to determine the best formulation for efficacy in the target human or animal. Suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol.

One or more of the above described vaccine components may be admixed or adsorbed with a conventional adjuvant. The adjuvant is used to attract leukocytes or enhance an immune response. Such adjuvants include, among others, Ribi, mineral oil and water, aluminum hydroxide, Amphigen, Avridine, L121/squalene, D-lactide-poly(lactide)/glycoside, pluronic polyols, muramyl dipeptide, killed *Bordetella*, and saponins, such as Quil A. In addition, a vaccine composition of the invention may further comprise other, non-*B. burgdorferi* antigens, including, *Bordetella bronchiseptica*, canine parvovirus, canine distemper, rabies, *Leptospiridia*, canine coronavirus, and canine adenovirus. Other vaccinal antigens originating from other species may also be included in these compositions, e.g., feline coronavirus, etc.

The invention thus also encompasses a prophylactic method entailing administering to an animal or human an effective amount of such a composition. The P39.5 and/or cassette string protein antigenic compositions are administered in an "effective amount", that is, an amount of antigen that is effective in a route of administration to provide a vaccinal benefit, i.e., protective immunity. Suitable amounts of the antigen can be determined by one of skill in the art based upon the level of immune response desired. In general, however, the vaccine composition contains between 1 ng to 1000 mg antigen, and more preferably, 0.05 µg to 1 mg per mL of antigen. Suitable doses of the vaccine composition of the invention can be readily determined by one of skill in the art. Generally, a suitable dose is between 0.1 to 5 mL of the vaccine composition. Further, depending upon the human patient or the animal species being treated, i.e. its weight, age, and general health, the dosage can also be determined readily by one of skill in the art.

In general, the vaccine will be administered once on a seasonal basis. Each tick season, usually in the spring, a booster should be administered. The vaccine may be administered by any suitable route. However, parenteral administration, particularly intramuscular, and subcutaneous, is the preferred route. Also preferred is the oral route of administration. Routes of administration may be combined, if desired, or adjusted.

Further, the vaccine may be a DNA vaccine, which includes the P7-1 DNA sequence or a fragment thereof, another cassette string protein, or a fragment thereof, optionally under the control of regulatory sequences. Thus, the antigen-encoding DNA may be carried in a vector, e.g., a viral vector. Generally, a suitable vector-based treatment contains between 1×10^{-3} pfu to 1×10^{12} pfu per dose. However, the dose, timing and mode of administration of these compositions may be determined by one of skill in the art. Such factors as the age, and physical condition of the vaccinee may be taken into account in determining the dose, timing and mode of administration of the immunogenic or vaccine composition of the invention.

VIII. Drug Screening and Development

The proteins, antibodies and polynucleotide sequences of the present invention may also be used in the screening and development of chemical compounds or proteins which have utility as therapeutic drugs or vaccines for the treatment or diagnosis or prevention of Lyme Disease. As one example, a compound capable of binding to P39.5 and preventing its biological activity may be a useful drug component for the treatment or prevention of Lyme Disease. The methods described herein may also be applied to fragments of P39.5. Similarly, a compound capable of binding to a cassette string protein, or fragment thereof and preventing its biological activity may be a useful drug component for the treatment or prevention of Lyme Disease.

Suitable assay methods may be readily determined by one of skill in the art. Where desired, and depending on the assay selected, the selected antigen(s), e.g., P39.5, may be immobilized directly or indirectly (e.g., via an anti-P39.5 antibody) on a

suitable surface, e.g., in an ELISA format. Such immobilization surfaces are well known. For example, a wettable inert bead may be used. Alternatively, the selected antigen, e.g., P39.5, may be used in screening assays which do not require immobilization, e.g., in the screening of combinatorial libraries. Assays and techniques exist for the screening and development of drugs capable of binding to an antigen of this invention, e.g., P39.5. These include the use of phage display system for expressing the antigenic protein(s), and using a culture of transfected *E. coli* or other microorganism to produce the proteins for binding studies of potential binding compounds. See, for example, the techniques described in G. Cesarini, FEBS Letters, 307(1):66-70 (July 1992); H. Gram *et al.*, J. Immunol. Meth., 161:169-176 (1993); C. Summer *et al.*, Proc. Natl. Acad. Sci., USA, 89:3756-3760 (May 1992), incorporated by reference herein.

Other conventional drug screening techniques may be employed using the proteins, antibodies or polynucleotide sequences of this invention. As one example, a method for identifying compounds which specifically bind to a protein of this invention, e.g., P39.5, can include simply the steps of contacting a selected P39.5 protein with a test compound to permit binding of the test compound to P39.5; and determining the amount of test compound, if any, which is bound to the P39.5 protein. Such a method may involve the incubation of the test compound and the P39.5 protein immobilized on a solid support. Similar methods may be employed for one or more of the cassette string proteins.

Typically, the surface containing the immobilized ligand is permitted to come into contact with a solution containing the protein and binding is measured using an appropriate detection system. Suitable detection systems include the streptavidin horse radish peroxidase conjugate, direct conjugation by a tag, e.g., fluorescein. Other systems are well known to those of skill in the art. This invention is not limited by the detection system used.

Another method of identifying compounds which specifically bind to P39.5 or another protein of this invention can include the steps of contacting the protein, e.g., P39.5, immobilized on a solid support with both a test compound and

the protein sequence which is a receptor for P39.5 to permit binding of the receptor to the P39.5 protein; and determining the amount of the receptor which is bound to the P39.5 protein. The inhibition of binding of the normal protein by the test compound thereby indicates binding of the test compound to the P39.5 protein. Similar methods
5 may be employed for one or more of the cassette string proteins.

Thus, through use of such methods, the present invention is anticipated to provide compounds capable of interacting with P39.5 or portions thereof, and/or the cassette string protein(s) or portions thereof and either enhancing or decreasing the protein's biological activity, as desired. Such compounds are believed to be
10 encompassed by this invention. Further wherever, above or below, the P39.5 protein is mentioned, it may be substituted with P7-1 or one or more of the other cassette string proteins.

The following examples illustrate the preferred methods for obtaining protein antigens of the invention and preparing the assays and compositions of the
15 invention. Significantly, these examples indicate that the P39.5 antigen of this invention is useful for diagnosis and prophylaxis against Lyme disease and may improve Lyme serology. These examples are illustrative only and do not limit the scope of the invention.

EXAMPLE 1 - BORRELIA BACTERIAL STRAINS AND ANTIBODIES

20 A. Bacterial Strains

The JD1 strain of *B. burgdorferi sensu stricto* [J. Piesman *et al.*, J. Clin. Microbiol., 25:557-558 (1987) and T. G. Schwan *et al.*, J. Clin. Microbiol., 27:1734-1738 (1989)] was obtained from the Center for Disease Control and Prevention and kept in frozen stocks of low passage (<7). B31 is also a strain of *B.*
25 *burgdorferi sensu stricto* obtained from the CDC and kept as above. IP90 is a strain of *B. garinii* which was also furnished by the CDC.

B. burgdorferi organisms were cultured at 34°C in a BSK-H culture medium (Sigma Chemical Co., St. Louis, Mo).

B. Monkey Antibodies

Live spirochetes were incubated with serum antibody from rhesus monkeys that had been infected with *B. burgdorferi* strain JD1 by the bite of *I. scapularis* nymphs. Unbound antibodies were washed off the spirochetes and bound antibodies were removed with a low pH buffer. Monkey antibodies were obtained from three sources:

a) from rhesus monkeys infected with *B. burgdorferi* strain JD1 by needle inoculation,

b) from rhesus monkeys infected with *B. burgdorferi* strain JD1 by exposure of the animals to JD1-infected nymphs of *Ixodes scapularis*,

c) by affinity purification on live spirochetes using as starting material antiserum that was collected from tick-inoculated animals, as follows: A volume of 800 μ l of diluted (1/40 in BSK-H medium), heat-inactivated serum samples pooled from 3 tick-inoculated animals are incubated with 1×10^9 total live bacteria at room temperature for 30 minutes. After the incubation, the samples were centrifuged at 13,000 x g for 15 minutes at 4°C. The supernatant was then reabsorbed two more times as described above. The bacterial pellet that was recovered after the first adsorption was washed three times with BSK-H to remove unbound antibodies. After the last wash, the pellet was resuspended in 400-500 μ l of 0.2 M glycine-HCl, pH 2.2, 0.5 M NaCl, and centrifuged. The supernatant was recovered and the pH brought to 7.00 by the addition of 2.0 M Tris base.

EXAMPLE 2 - PRELIMINARY IDENTIFICATION OF P39.5 OF IP90

The antibodies of Example 1, section B were reacted with Western blots of whole extracts from JD1, B31 and IP90 spirochetes. Western blots were performed as follows: Antigen preparations were electrophoresed in 15% acrylamide mini gels (10 X 10 X 0.1 cm) with a 5% acrylamide stacking gel. Twenty μ l of lysate containing 7×10^8 solubilized bacteria or 25 μ g of protein (measured by OD at 280 nm) were dispensed per track (the whole preparative track is equal to 16 single tracks; therefore 400 μ g protein were loaded onto each preparative gel). Electrophoresis was

performed using a mini-gel apparatus (Integrated Separation Systems, Hyde Park, MA) at a constant current of 23 mA, with the buffers of U. Laemmli, Nature, 227:680-685 (1970). For immunoblotting, the proteins from the polyacrylamide gels were electrotransferred to nitrocellulose paper (Schleicher and Schuell, Keene, NH) overnight at a constant voltage of 22 V in a Mighty Small transfer unit (Hoeffer Scientific Instruments, San Francisco, CA) as described by H. Towbin et al, Proc. Natl. Acad. Sci. USA, 76:4350-4354 (1979). Efficiency of transfer was assessed by staining part of the nitrocellulose with colloidal gold (Integrated Separation Systems). Nitrocellulose membranes were blocked with 3% fat-free powdered milk (Carnation) prepared in PBS containing 0.05% Tween-20 (Integrated Separation Systems) (PBS-T) for two hours at room temperature.

After the blocking step, the membranes were mounted in a Miniblotter (Immunetics, Cambridge, MA) according to the manufacturer's instructions, and 110 µl of each serum sample diluted 1/50 with PBS-T were introduced into the Miniblotter's channels and allowed to interact with the nitrocellulose membrane for 1 hour at room temperature on a rocking platform. After the incubation, the manifold system was used to wash the membranes with PBS-T. At this point the Miniblotter was disassembled and the blot was taken out. The rest of the incubation steps were performed in small trays. After the wash, the membranes were incubated for 1 hour with biotinylated anti-human IgM (µ-chain-specific) and IgG (γ-chain-specific) antibodies (Vector Laboratories, Burlingame, CA) diluted 1/200 in PBS-T. Biotinylated antibodies were probed with an avidin/biotinylated horseradish peroxidase complex (Vector) prepared according to the manufacturer's instructions. The reagent 4-chloro-1-naphthol (Sigma) was used as a chromogen. The color reaction was stopped by washing the membranes with distilled water.

A Western blot (Fig. 6) was prepared of lysates from spirochetes of *B. burgdorferi* strains JD1 and B31 and *B. garinii* strain IP 90 developed with serum from monkeys needle-inoculated and tick-inoculated with the JD1 spirochetes, and antibodies from the latter serum affinity purified off of whole live JD1 spirochetes. The affinity purified antibody recognized four antigens on Western blots of whole

lysates from spirochetes of *B. burgdorferi* JD1. The antigens were named P1 (Relative molecular mass (Mr) 39-40,000), P2 (Mr 35-37,000), P3 (Mr 22-24,000) and P4 (Mr 18-19,000). These antigens were also recognized, as expected, by serum samples from needle-inoculated animals and by serum from tick-inoculated monkeys. In addition, this Western blot indicated that the affinity-purified antibodies recognized what appeared to be P1, P2, and P4 on B31 spirochetes and what appeared to be P1 (but with a slightly higher relative molecular mass) in *B. garinii* as well as an additional antigen of higher relative molecular mass. These two latter antigens were also exclusively recognized by the sera from both needle- and tick-inoculated animals. P1 was eventually identified as P39, also known as BmpA. The similar antigen present on IP90 spirochetes was tentatively identified as P39.5 and was shown on the Western blot discussed above.

EXAMPLE 3 - ANTIBODY-DEPENDENT COMPLEMENT-MEDIATED KILLING OF JD1, B31 AND IP90 SPIROCHETES

Serum from tick-inoculated monkeys was employed in an ADCK assay as follows. Frozen samples of *B. burgdorferi* are quickly thawed at 37°C, cultured until they have reached mid-log phase (approximately 3 days, $1-2 \times 10^7$ spirochetes/ml), centrifuged at 8,000 X g for 20 minutes, resuspended in BSK-H medium, and counted. The ADCK assay was carried out in duplicate in 96-well tissue culture plates (Costar). A total of $5-6 \times 10^5$ spirochetes in 25 µl of BSK-H medium was added to each well containing 50 µl of heat-inactivated (56°C, 30 minutes) serum samples diluted to 1:10 in the same medium. The plates were incubated at 34°C under a gas mixture of 3% CO₂, 5% O₂ and the balance of N₂ for 20 minutes before the addition of 25 µl of complement (normal monkey serum). After 18-24 hours of incubation under the same conditions, the total numbers of dead (nonmotile) and live (motile) bacteria were quantified under a dark-field microscope. Equivalence between non-motility and death in a similar assay has been determined before [M. Aydintug et

al., cited above]. Killing was considered significant if the mean % of dead spirochetes exceeds three times the value of the mean % killing observed in the presence of normal serum.

ADCK was performed with spirochetes from *B. burgdorferi* strains JD1 and B31 and *B. garinii* strain IP90, using serum from animals that were tick inoculated with JD1 spirochetes. As shown in Example 2, this serum recognized only two antigens on IP90 blots, one of a relative molecular mass similar to that of P1, and one of higher relative molecular mass. As is shown in Fig. 1, all three spirochetal strains were killed by the serum, indicating that at least one of the antigens shown in the IP90 Western blot was the target of ADCK.

EXAMPLE 4 - IDENTIFICATION OF P39.5

The identity of the putative BmpA (P39) band seen on the IP90 Western blots was investigated. A Western blot of lysates from JD1 and IP90 was developed with anti-flagellin monoclonal antibody (Mab); anti-P39 Mab; anti-P39 polyclonal antibody; anti-P35 Mab; anti BmpD polyclonal; and sera from two monkeys tick-inoculated with JD1 spirochetes. In the comparative Western blot analysis of JD1 and IP90 antigens that were run on the same gel, both antigen extracts reacted with the anti-flagellin Mab H9724. However, an anti-BmpA Mab reacted only with JD1 BmpA, and serum from the monkey immunized with recombinant BmpA from JD1 reacted strongly with the JD1 blot, as expected, but very faintly with the BmpA antigen from IP90. Moreover, serum samples obtained from two JD1-infected monkeys reacted with the same two antigens as before on the IP90 blot and occasionally yielded additional (more faint) bands of higher molecular mass. The band of lowest molecular mass of the two corresponds in fact to a larger molecule than the BmpA from IP90, as identified with the anti-BmpA polyclonal antibody. The higher molecular mass band likely corresponds to flagellin, as it had the same molecular mass as the band of IP-90 that reacted with the MAb H9724.

A monoclonal antibody raised against P35 from JD1 reacted with this molecule on the JD1 blot but not on the IP90 blot, whereas a mouse polyclonal antiserum raised against JD1 BmpD reacted with BmpD of both JD1 and IP90, although the BmpD band of IP90 was very faint. Thus, the identity of the IP90 antigen that could be the target of the ADCK was not BmpA, BmpD or P35. It was referred to hereafter as P39.5.

A Western blot was then developed of lysates of JD1 and IP90 spirochetes incubated with serum from a monkey tick-inoculated with JD1; monkey polyclonal antiserum to P39; mouse Mab H9724 to flagellin; monkey anti-P39.5 antibody obtained by affinity purification from a serum sample from a monkey tick-inoculated with JD1; and mouse anti-recombinant P7-1 (rP7-1). To identify P39.5 on Western blots of JD1 lysates, the anti-P39.5 antibody elicited in JD1-infected monkeys was affinity purified using nitrocellulose strips that had P39.5 from IP90 attached to them. As expected, this antibody reacted with the P39.5 antigen on a Western blot of IP90 lysate but, surprisingly, failed to react with the JD1 blot. This result implied that P39.5 of JD1 was either not expressed *in vitro*, was sparsely expressed as to be undetectable by the affinity-purified anti-P39.5 antibody on the JD1 blots, or was expressed *in vitro* by JD1 in a manner that was not cross-reactive antigenically with the antibody affinity purified off of the P39.5 of IP90.

Obviously, JD1 spirochetes had to express P39.5 *in vivo* and in amounts sufficiently high as to be immunogenic, since otherwise the anti-P39.5 antibody that was affinity purified would not have been elicited in the first place. In the above described Western blot, the position of BmpA was indicated by its reaction with the anti-BmpA polyclonal antiserum and that of flagellin by the reaction of this molecule with Mab H9724.

A new *Borrelia* antigen that is abundantly expressed *in vitro* by the *B. garinii* strain IP90 and *in vivo* by the *B. burgdorferi sensu stricto* strain JD1 was thus identified. This antigen, P39.5, was the target in the ADCK of IP90 spirochetes.

EXAMPLE 5 - CLONING OF P39.5*A. Cloning in bacteriophage*

A library of randomly-sheared total DNA from *B. garinii* IP90 was constructed in the λ ZAPII bacteriophage vector [Stratagene, La Jolla, CA] and screened with a pool of plasma collected from rhesus monkeys infected with the JD1 strain of *B. burgdorferi*. The plasma samples used for the pool were selected such that they contained antibody that recognized only P39.5, the putative flagellin and the 1 or 2 additional unidentified higher molecular mass faint bands seen on some IP90 Western blots.

After several rounds of screening, eleven clones were rescued into the pBluescript phagemid [Stratogene] the recombinant plasmids were purified and used to transform cells of the SURE strain of *E. coli*. Several transformants were selected from each original clone, the presence of the insert was confirmed, and one such transformant from each clone was grown, induced for expression, lysed and analyzed by Western blot with the original plasma pool. The eleven cloned fragments hybridized to each other by dot-blot hybridization.

One of the eleven clones (named 7-1) was selected for over-expression and purification on the basis of the strong reactivity of the expressed protein with the plasma antibodies. The 7-1 insert was 950bp in length.

The identity of the expressed protein was confirmed as antigenically identical to, or cross-reactive with, P39.5, by showing that antibody from the original plasma sample that was affinity purified using the clone as immunoabsorbant reacted with P39.5 on a Western blot of *B. garinii* lysate. A Western blot was developed of lysates from IP90 spirochetes reacted with plasma from a monkey infected with JD1 spirochetes; antibody from the same plasma affinity purified with the recombinant antigens as expressed by *B. garinii* clone 1-1 and clone 7-1. Reactivity of the IP90 lysate with the monkey plasma pool was demonstrated in the blot. Reactivity of the IP90 lysate with the antibody affinity purified with the recombinant 1-1 protein was shown, and with the antibody affinity purified with the recombinant 7-1 protein.

A partial DNA sequence for P7-1 was obtained [SEQ ID NO: 1]. About 950bp were derived from clone 7-1. In addition, about 140 kb of the upstream regions were obtained from clone 14 [SEQ ID NO: 13]. The DNA fragment formed by the 5' SEQ ID NO: 13 sequence and the SEQ ID NO: 1 sequence is 1189 bp in length, which is depicted in Fig. 2. It encompasses a single open reading frame which encodes a deduced protein of 37.7 kDa. Its high alanine content results in this rather low molecular mass. Since the average molecular mass of this protein's amino acids is 95, there are about 57 bp of the complete coding region missing. Since no hydrophobic leader sequence was observed and since P39.5 has the solubility properties of lipoproteins (see below), it follows that P7-1 is antigenically cross-reactive with P39.5, but is not the complete P39.5 itself.

Data other than the deduced amino acid sequence of P7-1 [SEQ ID NOS: 14 and 2] suggests that P39.5 is a lipoprotein. First, the native form of P39.5 present in whole-cell extracts of IP90 spirochetes was fully extractable, i.e., partitions into, the detergent phase in a Triton-X114 phase separation experiment. Second, most of its sequence is composed of hydrophilic domains, very much like OspA, yet it must be expressed on the outer surface, since it is targeted by antibody. Third, its % identity with several members of the Vmp family of *Borrelia hermsii* lipoproteins is considerable, e.g., 22% with Vmp4, 19% with Vmp23, 18% with Vmp17, and 17% with Vmp21. These sequences are available on the GENBANK database.

An interesting feature of its nucleotide sequence is the presence of several internally repeated regions, shown in Fig. 2. Blocks IA and IB are 70% identical. Block IIA is as much as 91% identical to IIB, and blocks A, B and C are between 84 and 90% identical. The only internally unique fragment is that denoted by the black block. Clearly, such a molecule will be prone to undergoing homologous recombinations of the same kind that occur between and within the OspA and OspB genes, which have regions of homology [P. Rosa *et al*, cited above]. However, such

potential escape mutants may not escape the combined action of antibody and complement, as demonstrated by reference to the case of OspA [Sole et al, cited above].

5 *B. Expression and purification of recombinant P7-1 with the QIAEXPRESS™ System*

The Qiaexpress™ system from Qiagen, Inc. (Chatsworth, CA) takes advantage of the high affinity of six consecutive histidine residues for divalent cations such as Ni. The latter is conjugated to nitrilo-tri-acetic acid (NTA), which in turn is linked to agarose. Since the affinity tag is very small (minimally 6 residues) it
10 may be left in the fusion protein without serious consequences with regard to the protein antigenic properties. The 6xHis affinity tag may be incorporated either at the N- or C-terminus. A range of vectors (pQE vectors) are available for constructing both types of fusion.

Recombinants were initially screened for the presence of
15 expected inserts in the plasmids. This was followed by a Western blot to confirm protein expression in these recombinants. Westerns blots were developed either with serum from control mice infected with the spirochetes of the corresponding strain or with a mouse antibody that specifically detects the MRGS(His)6 epitope (Qiagen), which was the affinity tag sequence present in some of the pQE vectors [for N-
20 terminal fusions]. An equally sensitive alternative was to use Ni-NTA-alkaline phosphatase conjugate, which was also available from Qiagen.

The *E. coli* cells containing the fusion construct were grown to mid-log phase, induced with 0.3 mM IPTG for a period of three hours, pelleted, washed once with Sonication buffer [50 mM NaPO₄, pH 8.0, 300 mM NaCl] and
25 stored overnight at -20°C. On the next day, cells were resuspended in Sonication buffer and sonicated on ice using 15-second pulses for a total of 2 minutes. Immediately following sonication the serine protease inhibitor PMSF (phenyl-methyl-sulfonide fluoride) was added to prevent degradation by such proteases. The cell debris was spun down, and the supernatant transferred to a fresh tube. In the mean
30 time, the Ni-NTA resin was washed once with 10 column volumes (cv) of the

Sonication buffer. The fusion protein was allowed to bind to the Ni-NTA resin in a tube for 1 hour. The resin was spun down and the supernatant discarded. The resin was resuspended in 10 cv of Sonication buffer, poured into a column and washed 3 times with 10 cv of the same buffer followed by 3 10-cv washes with Wash buffer [50 mM NaPO₄, pH 6.3, 300 mM NaCl]. Finally, the fusion protein was eluted with 10 cv of Elution buffer [50 mM NaPO₄, pH 4.5, 300 mM NaCl] and fractions collected. Fractions were assayed for protein and the fractions that contain the highest protein concentration pooled and neutralized to pH 7.0 with dibasic NaPO₄. The protein concentration in the pooled sample was calculated and an aliquot run on a SDS-PA gel and stained with silver to check purity. Typical yields were about 4-5 mg/liter of culture.

EXAMPLE 6 - IN VITRO PROTECTIVE POTENTIAL OF P7-1 IN MONKEYS

Anti-P7-1 antibody was purified from the same monkey plasma pool used to screen the DNA library, by absorbing and acid-eluting it off of nitrocellulose strips that contained the recombinant P7-1 protein (rP7-1) as expressed from clone 7-1. The monospecificity of the antibody was confirmed on a Western blot as described in Examples 2 and 4, and the antibody was used in ADCK as described in Example 3.

The fraction of dead IP90 spirochetes after a 24 hour incubation with the affinity purified anti-P7-1 antibody was 55% (Fig. 3, bar 2). The antibody was reconstituted at a concentration equivalent to a 1:10 dilution of its concentration in plasma. This killing rate was comparable to that observed with a 1:10 dilution of the same plasma (67%, Fig. 3, bar 1). Complement was essential to effect killing, as only 12% of the spirochetes was killed in its absence (Fig. 3, bar 3). Killing in the presence of monkey complement alone was slightly higher than usual, in that the value was 25% (Fig. 3, bar 4) whereas the value most frequently obtained was 10-15%, albeit with JD1 spirochetes [M. Aydintug *et al*, *Infect. Immun.*, 62:4929-4937 (1994)]. In BSK-H medium alone 12% of the spirochetes died (bar 5).

These results indicated that antibody to the recombinant P7-1 (a fragment of P39.5) antigen of IP90, elicited in monkeys during the course of a natural infection with JD1 spirochetes, could kill IP90 spirochetes by ADCK.

These experiments demonstrated the protective potential of P7-1 and
5 formed the basis of selection of this antigen as a vaccine candidate.

EXAMPLE 7 - PROTECTIVE POTENTIAL OF P7-1 IN MICE

This example shows that mice may be directly immunized with the recombinant P7-1. The mouse antibodies generated by immunization with rP7-1 and Ribi adjuvant were able to kill up to 60% of IP90 spirochetes *in vitro*, by antibody-
10 dependent, complement-mediated killing (ADCK). To assess the protective potential of P7-1 more directly, the DNA fragment of clone 7-1 was subcloned in the pQE as described in Example 5, and the expressed protein was purified in milligram quantities and used to immunize C3H/HeJ mice. Mice were given four injections of 30 µg each of the recombinant P7-1 in 0.2 ml of Ribi R-700 adjuvant (Ribi ImmunoChem
15 Research, Inc., Hamilton, MT). The R-700 formulation of 0.25 mg/ml MPL™, 0.25 mg/ml synthetic trehalose dicorynomycolate, 20 µl/ml Squalene (hexamethyl-tetracosahexane) and 2 µl/ml monooleate (Tween 80). Injections were given intraperitoneally, three weeks apart. Two weeks after the last immunization, mice were bled, specificity of the elicited antibody was confirmed by Western blot using
20 whole cell extracts of IP90 spirochetes as antigen, and serum samples were pooled.

Serum from mice immunized with the Ribi adjuvant alone recognized no antigens on IP90 blots. Serum from mice immunized with rP7-1 and Ribi recognized, as expected, the P39.5 band on IP90 lysates, but also a weaker band slightly above the 41 kDa flagellin band, and a higher molecular mass band as well.
25 Interestingly, this same mouse antibody recognized a 41 kDa band on Western blots of JD1 lysates, and also a slightly higher molecular mass antigen.

This result differed from that obtained with affinity-purified anti-rP7-1 antibody from monkeys in the preceding example and was probably due to the fact that the mouse antibody's affinity was allowed to mature for much longer (12 weeks)

than that of the monkey antibody (4-5 weeks). As a consequence, its binding affinity was higher but its specificity was lower and it can bind to crossreactive but nonidentical epitopes.

After an additional booster injection, the mice that yielded the anti-P7-1 antibody that killed 60% of IP90 spirochetes by ADCK *in vitro* yielded an antiserum that killed 100% of such spirochetes in an experiment of the same kind. In addition, this same antiserum was able to kill 50% of spirochetes from strain NT1 (a strain as yet untyped but probably *sensu stricto*, as it was isolated from the cerebrospinal fluid of a patient in the North East of the United States). In contrast, no spirochetes of the JD1 strain could be killed either *in vitro* (by ADCK) or *in vivo*, in a tick-challenge experiment with mice immunized with rP7-1 and Ribi adjuvant.

ADCK was assessed both with monkey and with guinea pig complement. Normal guinea pig serum (from Sigma Chemical Co., St. Louis, MO) was used as a source of complement in the latter case. The same monkey plasma pool from animals infected with *B. burgdorferi* JD1 was used as a positive control. At a dilution of 1:10, this plasma pool killed 57% of IP90 spirochetes after a 24 hour incubation (Fig. 3, bar 1). Mouse antiserum to the rP39.5 killed 73.5% of the spirochetes at a dilution of 1:10 and 60.5% at 1:50 (bars 2 and 3, respectively). Serum from mice immunized with Ribi adjuvant alone killed 21% of the spirochetes (bar 4). Guinea pig complement was less effective in the ADCK assay. A fraction of 37% of the spirochetes was killed with the positive control plasma at 1:10 (bar 5) whereas the mouse anti-P39.5 antiserum at the same dilution killed 48% of the spirochetes in the presence of Guinea pig complement (bar 6). A fraction of 12% of the spirochetes was killed in the presence of a 1:10 dilution of serum from mice given Ribi alone (bar 7). Interestingly, only 6% of JD1 spirochetes were killed when incubated with a 1:10 dilution of the mouse anti-r39.5 antiserum, a fraction that did not differ from that killed with just control serum (not shown). Hence, the bands recognized on the JD1 blot probably represent a spurious crossreactivity, but not the JD1 P39.5.

EXAMPLE 8 - DIAGNOSTIC USE OF P7-1 IN HUMANS

Nineteen human serum samples were obtained from the Centers for Disease Control and Prevention (CDC). Four of these samples were from donors who had no history of Lyme disease and had never resided in an area where this disease is endemic. The other fifteen samples were from patients who lived in Lyme disease endemic areas, had signs and/or symptoms of the disease, and, with the exception of one patient, were serologically positive by the criterion recommended by the CDC. That criterion provides that patients be positive by a sensitive Lyme ELISA test and be also positive by either an IgM or an IgG Western blot, such that at least two of the following three bands were present in positive IgM blots (24, 39, or 41 kDa) and five of the following ten bands were present in positive IgG blots (18, 21, 28, 30, 39, 41, 45, 58, 66, and 93 kDa).

The test, based on detection of IgG antibody by incubating serum samples diluted at 1:200 with nitrocellulose strips onto which purified P39.5 antigen had been electroblotted, and subsequent detection of bound antibody by the immunoenzymatic methods described in Example 2, yielded the following results. The four serum samples from donors who had no history of Lyme disease and had never resided in an area where this disease is endemic had no detectable anti-P39.5 antibody. Of the fifteen remaining samples, fourteen were positive. The only negative sample was that which also had failed to show antibody by the criterion recommended by the CDC. Thus, the simple procedure described herein based on the P39.5 antigen as a diagnostic probe for anti-*B. burgdorferi* antibody is, by this initial assessment, as sensitive and specific as the more complex two-step method that is currently recommended by the CDC.

In another diagnostic assay, the antigenic protein expressed from the 7-1 DNA fragment, rP7-1, was tested as a probe for the early serological diagnosis of Lyme disease in rhesus monkeys. Serum samples obtained from three pairs of rhesus monkeys infected with three different strains of *B. burgdorferi*, B31, JD1 and NT1, respectively, contained detectable antibody to purified rP7-1 by week 2 of infection, as detected by Western blot. Both IgM and IgG antibodies were tested

simultaneously. The result indicates that antibody to P7-1 appears early in the course of infection, regardless of the strain of *B. burgdorferi* that is eliciting the antibody response.

The sensitivity of antibody detection was assessed again by Western blot as above, with a battery of 43 human serum samples obtained from the CDC. The experiment was performed in a blinded fashion. The CDC samples had been obtained from patients with a clinical diagnosis of Lyme disease that satisfied the stringent CDC criteria for case definition. Of the 43 samples from clinically positive patients, 34 were reported positive by the CDC, as judged by the Dressler criteria [Dressler, F. et al, 1993 J. Infect. Dis., 167:392-40] using the Western blot test from MarDx Diagnostics, Inc. (Lyme disease MarBlot). With the diagnostic Western blot based on the P7-1 antigen, an equal number of samples were positive (34), although negative or positive results did not always coincide in both assays. Thus, the P7-1-based Western, in which a single band is (or is not) detected and which is therefore a test simple to interpret, yielded the same sensitivity as one of the most accomplished, yet cumbersome to interpret, Lyme disease diagnostic tests presently in the market.

In tests for antigenic specificity, so far, from 12 serum samples of syphilitic patients, 11 were negative with the assay despite the fact that all of the samples contained antibodies that cross-reacted with multiple antigens on a Western blot of whole *B. burgdorferi* antigens. The single serum sample that gave a positive result was from a patient who also had an HIV infection and several AIDS-related infections.

EXAMPLE 9 - THE CASSETTE STRING PROTEINS

As stated above, the amino acid sequence predicted from the nucleotide sequence of the 7-1 fragment is about 50% identical to the VlsE of the B31 strain of *B. burgdorferi*, which is part of an antigen of *B. burgdorferi* that undergoes antigenic variation by a mechanism of recombination whereby a central fragment of the expressed copy (VlsE) is recombined with fragments from a string of 15 "cassettes" located upstream from the expressed copy [J. Zhang, cited above].

Several DNA fragments have been cloned which appear to be part of the cassette string of *B. garinii* IP90. In addition to 7-1, these fragments, named 1-1, 3-1, 6-1, 9-1, and 12-1 are between 1 and 2 kb in length. When expressed in recombinant form, substantially as described above for P7-1 (off of the lacZ promoter of pBluescript), each of the cassette string fragments expresses a peptide which is commensurate with the size of the insert and which reacts with antibody from infected monkeys. None of the 5' ends of these fragments contains a hydrophobic leader or a signal peptidase II consensus sequence of the type that is characteristic of bacterial lipoproteins. These fragments must therefore be part of the cassette string of IP90 and, like the cassette string of B31, they are in-frame. DNA sequences of the 5' and 3' termini (between about 100-500 bp) of each fragment are illustrated in SEQ ID NOS: 3 through 12. Note that only the 5' end of fragment 9-1 is illustrated in SEQ ID NO: 10.

The antigenicity of these fragments has been analyzed in two ways. First, the reactivity of the fragments' Western blots with serum samples collected longitudinally from rhesus monkeys was studied over a period of 48 weeks after a tick inoculation with *B. burgdorferi* JD1. Proteins expressed by fragments 9-1 and 7-1 reacted predominantly with serum samples collected between weeks 2 and 24 post-infection (PI) (early reactors), proteins expressed by fragments 3-1 and 6-1 reacted chiefly with serum samples collected between weeks 24 and 48 PI (late reactors), and proteins from fragments 1-1 and 12-1 showed a largely uniform reactivity over the 48-week-long time span investigated. This result suggests that each of the cloned fragments contains unique epitopes.

To confirm this notion, a serum pool was constructed with the samples employed in the Western blot analysis described above, and an aliquot of this "time" pool was pre-incubated with an excess of the purified antigen expressed from 7-1 (rP7-1). In this way, the anti-P7-1 antibody that was present in the serum pool was no longer available to react with the P7-1 antigen on Western blots. Nonetheless, this serum pool was still able to react with the proteins expressed from the other DNA fragments, with the exception of 12-1. Since the latter is a "late" reactor, it is possible

that antibodies to the putatively unique epitopes of 12-1 may have been diluted out in the serum pool. All of the above fragment were subcloned into the pQE vector for expression using conventional methodologies, as described above for P7-1.

The inventor has theorized that the mechanism of antigenic variation to which the IP90 P39.5 antigen is subjected, by virtue of its homology to the vls E antigens of B31, indicates that this antigen is crucially important for spirochetal survival in the vertebrate host. Thus, the methods and compositions of this invention are designed to circumvent this spirochetal defense mechanism by immunizing a host with a large fraction of the epitopes that are expressed on the cassette string that is the very source of the variation. This is made possible by the unique fact that most of this cassette string is in frame. Therefore, as mentioned above, one method of vaccination involves administering to the host several or all of the cloned and purified proteins described above, which are derived from antigenically dissimilar sections of the IP90 cassette string. See, e.g., the results obtained when P7-1 was introduced into a host and induced antibodies which killed the spirochetes.

All above-noted references and priority document are incorporated herein by reference. Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. Such modifications and alterations to the compositions and processes of the present invention are believed to be encompassed in the scope of the claims appended hereto.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Administrators of Tulane Educational Fund
Philipp, Mario T.
- (ii) TITLE OF INVENTION: Surface Antigens and Proteins Useful in
Compositions for the Diagnosis and Prevention of Lyme
Disease
- (iii) NUMBER OF SEQUENCES: 14
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Howson and Howson
 - (B) STREET: Spring House Corporate Cntr., P.O. Box 457
 - (C) CITY: Spring House
 - (D) STATE: Pennsylvania
 - (E) COUNTRY: USA
 - (F) ZIP: 19477
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: WO
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 60/051,271
 - (B) FILING DATE: 30-JUN-1997
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Bak, Mary E.
 - (B) REGISTRATION NUMBER: 31,215
 - (C) REFERENCE/DOCKET NUMBER: TUL2APCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 215-540-9200
 - (B) TELEFAX: 215-540-5818

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1047 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: cDNA

53

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1047

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAG AAT AAT GAT CAT GAT AAT CAT AAG GGG ACT GTT AAG AAT GCT GTT	48
Lys Asn Asn Asp His Asp Asn His Lys Gly Thr Val Lys Asn Ala Val	
1 5 10 15	
GAT ATG GCA AAG GCC GCT GAG GAA GCT GCA AGT GCT GCA AGT GCT GCT	96
Asp Met Ala Lys Ala Ala Glu Glu Ala Ala Ser Ala Ala Ser Ala Ala	
20 25 30	
ACT GGT AAT GCA GCG ATT GGG GAT GTT GTT AAG AAT AGT GGG GCA GCA	144
Thr Gly Asn Ala Ala Ile Gly Asp Val Val Lys Asn Ser Gly Ala Ala	
35 40 45	
GCA AAA GGT GGT GAG GCG GCG AGT GTT AAT GGG ATT GCT AAG GGG ATA	192
Ala Lys Gly Gly Glu Ala Ala Ser Val Asn Gly Ile Ala Lys Gly Ile	
50 55 60	
AAG GGG ATT GTT GAT GCT GCT GGA AAG GCT GAT GCG AAG GAA GGG AAG	240
Lys Gly Ile Val Asp Ala Ala Gly Lys Ala Asp Ala Lys Glu Gly Lys	
65 70 75 80	
TTG GAT GCT ACT GGT GCT GAG GGT ACG ACT AAC GTG AAT GCT GGG AAG	288
Leu Asp Ala Thr Gly Ala Glu Gly Thr Thr Asn Val Asn Ala Gly Lys	
85 90 95	
TTG TTT GTG AAG AGG GCG GCT GAT GAT GGT GGT GAT GCA GAT GAT GCT	336
Leu Phe Val Lys Arg Ala Ala Asp Asp Gly Gly Asp Ala Asp Asp Ala	
100 105 110	
GGG AAG GCT GCT GCT GCG GTT GCT GCA AGT GCT GCT ACT GGT AAT GCA	384
Gly Lys Ala Ala Ala Val Ala Ala Ser Ala Ala Thr Gly Asn Ala	
115 120 125	
GCG ATT GGA GAT GTT GTT AAT GGT GAT GTG GCA AAA GCA AAA GGT GGT	432
Ala Ile Gly Asp Val Val Asn Gly Asp Val Ala Lys Ala Lys Gly Gly	
130 135 140	
GAT GCG GCG AGT GTT AAT GGG ATT GCT AAG GGT ATA AAG GGG ATT GTT	480
Asp Ala Ala Ser Val Asn Gly Ile Ala Lys Gly Ile Lys Gly Ile Val	
145 150 155 160	
GAT GCT GCT GAG AAG GCT GAT GCG AAG GAA GGG AAG TTG AAT GCT GCT	528
Asp Ala Ala Glu Lys Ala Asp Ala Lys Glu Gly Lys Leu Asn Ala Ala	
165 170 175	
GGT GCT GAG GGT ACG ACT AAC GCG GAT GCT GGG AAG TTG TTT GTG AAG	576
Gly Ala Glu Gly Thr Thr Asn Ala Asp Ala Gly Lys Leu Phe Val Lys	
180 185 190	
AAT GCT GGT AAT GTG GGT GGT GAA GCA GGT GAT GCT GGG AAG GCT GCT	624
Asn Ala Gly Asn Val Gly Gly Glu Ala Gly Asp Ala Gly Lys Ala Ala	
195 200 205	

54

GCT GCG GTT GCT GCT GTT AGT GGG GAG CAG ATA TTA AAA GCG ATT GTT Ala Ala Val Ala Ala Val Ser Gly Glu Gln Ile Leu Lys Ala Ile Val 210 215 220	672
CAT GCT GCT AAG GAT GGT GGT GAG AAG CAG GGT AAG AAG GCT GCG GAT His Ala Ala Lys Asp Gly Gly Glu Lys Gln Gly Lys Lys Ala Ala Asp 225 230 235 240	720
CGT ACA AAT CCC ATT GAC GCG GCT ATT GGG GGT GCG GGT GAT AAT GAT Arg Thr Asn Pro Ile Asp Ala Ala Ile Gly Gly Ala Gly Asp Asn Asp 245 250 255	768
GCT GCT GCG GCG TTT GCT ACT ATG AAG AAG GAT GAT CAG ATT GCT GCT Ala Ala Ala Ala Phe Ala Thr Met Lys Lys Asp Asp Gln Ile Ala Ala 260 265 270	816
GCT ATG GTT CTG AGG GGA ATG GCT AAG GAT GGG CAA TTT GCT TTG AAG Ala Met Val Leu Arg Gly Met Ala Lys Asp Gly Gln Phe Ala Leu Lys 275 280 285	864
GAT GCT GCT GCT GCT CAT GAA GGG ACT GTT AAG AAT GCT GTT GAT ATA Asp Ala Ala Ala Ala His Glu Gly Thr Val Lys Asn Ala Val Asp Ile 290 295 300	912
ATA AAG GCT GCT GCG GAA GCT GCA AGT GCT GCA AGT GCT GCT ACT GGT Ile Lys Ala Ala Ala Glu Ala Ala Ser Ala Ala Ser Ala Ala Thr Gly 305 310 315 320	960
AGT GCA GCA ATT GGG GAT GTT GTT AAT GGT AAT GGA GCA ACA GCA AAA Ser Ala Ala Ile Gly Asp Val Val Asn Gly Asn Gly Ala Thr Ala Lys 325 330 335	1008
GGT GGT GAT GCG AAG AGT GTT AAT GGC ATT GCT AAG GGA Gly Gly Asp Ala Lys Ser Val Asn Gly Ile Ala Lys Gly 340 345	1047

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 349 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Lys Asn Asn Asp His Asp Asn His Lys Gly Thr Val Lys Asn Ala Val 1 5 10 15
Asp Met Ala Lys Ala Ala Glu Glu Ala Ala Ser Ala Ala Ser Ala Ala 20 25 30
Thr Gly Asn Ala Ala Ile Gly Asp Val Val Lys Asn Ser Gly Ala Ala 35 40 45

55

Ala Lys Gly Gly Glu Ala Ala Ser Val Asn Gly Ile Ala Lys Gly Ile
 50 55 60
 Lys Gly Ile Val Asp Ala Ala Gly Lys Ala Asp Ala Lys Glu Gly Lys
 65 70 75 80
 Leu Asp Ala Thr Gly Ala Glu Gly Thr Thr Asn Val Asn Ala Gly Lys
 85 90 95
 Leu Phe Val Lys Arg Ala Ala Asp Asp Gly Gly Asp Ala Asp Asp Ala
 100 105 110
 Gly Lys Ala Ala Ala Val Ala Ala Ser Ala Ala Thr Gly Asn Ala
 115 120 125
 Ala Ile Gly Asp Val Val Asn Gly Asp Val Ala Lys Ala Lys Gly Gly
 130 135 140
 Asp Ala Ala Ser Val Asn Gly Ile Ala Lys Gly Ile Lys Gly Ile Val
 145 150 155 160
 Asp Ala Ala Glu Lys Ala Asp Ala Lys Glu Gly Lys Leu Asn Ala Ala
 165 170 175
 Gly Ala Glu Gly Thr Thr Asn Ala Asp Ala Gly Lys Leu Phe Val Lys
 180 185 190
 Asn Ala Gly Asn Val Gly Gly Glu Ala Gly Asp Ala Gly Lys Ala Ala
 195 200 205
 Ala Ala Val Ala Ala Val Ser Gly Glu Gln Ile Leu Lys Ala Ile Val
 210 215 220
 His Ala Ala Lys Asp Gly Gly Glu Lys Gln Gly Lys Lys Ala Ala Asp
 225 230 235 240
 Arg Thr Asn Pro Ile Asp Ala Ala Ile Gly Gly Ala Gly Asp Asn Asp
 245 250 255
 Ala Ala Ala Ala Phe Ala Thr Met Lys Lys Asp Asp Gln Ile Ala Ala
 260 265 270
 Ala Met Val Leu Arg Gly Met Ala Lys Asp Gly Gln Phe Ala Leu Lys
 275 280 285
 Asp Ala Ala Ala Ala His Glu Gly Thr Val Lys Asn Ala Val Asp Ile
 290 295 300
 Ile Lys Ala Ala Ala Glu Ala Ala Ser Ala Ala Ser Ala Ala Thr Gly
 305 310 315 320
 Ser Ala Ala Ile Gly Asp Val Val Asn Gly Asn Gly Ala Thr Ala Lys
 325 330 335
 Gly Gly Asp Ala Lys Ser Val Asn Gly Ile Ala Lys Gly
 340 345

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 283 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GCCGCTGGAT GGTGGTGAGA AGCAGGGTAA GAAGGCTGCG GATCGTACAA ATCCCATTGA	60
CGCGGCTATT GGGGGTGCGG GTGATAATGA TGCTGCTGCG GCGTTTGCTA CTATGAAGAA	120
GGATGATCAG ATTGCTGCTG CTATGGTTCT GAGGGGAATG GCTAAGGATG GGCAATTTGC	180
TTTGAAGGAT GCTGCTGCTG CTCATGAAGG GACTGTTAAG AATGCTGTTG ATATAATAAA	240
GGCTGCTGCG GAAGCTGCAA GTGCTGCAAG TGCTGCTACT GGT	283

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 233 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TTTATTATAT CAACAGATTC TTAACAGTCC CTTTCATGAGC AGCAGCAGCA TCCTTCAAAG	60
CAAATTGCCC ATCCTTAGCC ATTCCCCTCA GAACCATAGC AGCAGCAATC TGATCATCCT	120
TCTTCATAGT AGCAAACGCC GCAGCAGCAT CATTATCACC CGCACCCCCA ATAGCCGCGT	180
CAATCGGATT TGTACGATCC GCAGCCTTCT TACCCTGCTT CTCACCACCA TCC	233

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 194 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

57

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCGTGCAAGC TGGGTTGAAG AAGGTTGGGG ATGTTGTTAA GAATAGTGAG GCAAAAGATG 60
GTGATGCGGC GAGTGTTAAT GGGATTGCTA AGGGGATAAA GGGGATTGTT GATGCTGCTG 120
AGAAGGCTGA TCGAAGGAA GGGAAATTGG TATGTGGCTG GTGCTGCTGG TGAAACTAAC 180
AAGGAAGCGG CCGC 194

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 369 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GCGGCCGCTT GAGGAAGCTG CAAGTGCTGC AAGTGCTGCT ACTGGTAATG CAGCGATTGG 60
GGATGTTGTT AAGAATAGTG GGGCAGCAGC AAAAGGTGGT GAGGCGGCGA GTGTTAATGG 120
GATTGCTAAG GGGATAAAGG GGATTGTTGA TGCTGCTGGA AAGGCTGATG CGAAGGAAGG 180
GAAGTTGGAT GCTACTGGTG CTGAGGGTAC GACTAACGTG AATGCTGGGA AGTTGTTTGT 240
GAAGAGGGCG GCTGATGATG GTGGTGATGC AGATGATGCT GGGAAAGGCTG CTGCTGCGGT 300
TGCTGCAAGT GCTGCTACTG GTAATGCAGC GATTGGAGAT GTTGTTAATG GTGATGTGGC 360
AAAACAAAA 369

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 142 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AAGGATGGTG ATGATAAGCA GGGTAAGAAG GCTGAGGATG CTACAAATCC GATTGACGCG 60
GCTATTGGGG GTGCAGGTGC GGGTGCTAAT GCTGCTGCGG CGTTTAATAA TATGAAGAAG 120
GATGATCAGA TTGAGCGGCC GC 142

58

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 210 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GGTGAACTA ACAAGGATGC TGGGAAGTTG TTTGTGAAGA AGAATGGTGA TGATGGTGGT	60
GATGCAGGTG ATGCTGGGAA GGCTGCTGCT GCGGTTGCTG CTGTTAGTGG GGAGCAGATA	120
TTAAAAGCGA TTGTTGATGC TGCTAAAGAT GGTGATAAGA CGGGGGTTAC TGATGTAAAG	180
GATGCTACAA ATCCGATTGA CGCGGCTATT	210

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 236 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TATATAATAA AGGCTGCTGC GAAGCTGCAA GTGCTGCAAG TGCTGCTACT GGTAGTGCAG	60
CAATTGGGGA TGTTGTTAAT GGTAATGGAG CAACAGCAAA AGGTGGTGAT GCGAAGTGTT	120
AATGGGATTG CTAAGGGGAT AAAGGGGATT GTTGATGCTG CTGAGAAGGC TGATGCGAAG	180
GAAGGGAAGT TGGATGTGGC TGGTGATGCT GGTGAACTA ACAAGGAAGC GGCCGC	236

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 199 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

ATGAGAGGAT CTCATCACCA TCACCATCAC ACGGATCCCC CGGGCTGCAG GAATTCGCGG	60
CCGCTGAAGG CTGATGCGAA GGAAGGGAAG TTGGATGTGG CTGGTGCTGC TGGTGAAACT	120

AACAAGGATG CTGGGAAGTT GTTTGTGAAG AAGAATAATG AGGGTGGTGA AGCAAATGAT 180
GCTGGGAAGG CTGCTGCTG 199

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 272 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GCCGCTGGAT GATCAGATTG CTGCTGCTAT GGTGTGAGG GGAATGGCTA AGGATGGGCA 60
GTTTGCTTTG AAGGATGATG CTGCTAAGGA TGGAGATAAA ACGGGGGTTG CTGCGGATGT 120
GAAAATCCGA TTGACGCGGC TATTGGGGGT GCGGATGCTG ATGCTGCGGC GTTTAATAAG 180
GAGGGGATGA AGAAGGATGA TCAGATTGCT GCTGCTATGG TTCTGAGGGG AATGGCTAAG 240
GATGGGCAGT TTGCTTTGAC GAATAATGCT GC 272

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 289 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

ACTGTTAAGA ATGCTGTTGA TATAATAAAG GCTGCTGCGG AAGCTGCAAG TGCTGCAAGT 60
GCTGCTACTG GTAGTGCAGC AATTGGGGAT GTTGTTAATG GTAATGGAGC AACAGCAAAA 120
GGTGGTGATG CGAAGAGTGT TAATGGGATT GCTAAGGGGA TAAAGGGGAT TGTTGATGCT 180
GCTGAGAAGG CTGATGCGAA GGAAGGGAAG TTGGATGTGG CTGGTGATGC TGGTGAAACT 240
AACAAGGATG CTGGGAAGTT GTTTGTGAAG AACAATGGTA ATGAGGGTA 289

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 142 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

60

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 2..142

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

G CCG CTT ACA AAT CCG ATT GAC GCG GCT ATT GGG GGG AGT GCG GAT	46
Pro Leu Thr Asn Pro Ile Asp Ala Ala Ile Gly Gly Ser Ala Asp	
1 5 10 15	
CGT AAT GCT GAG GCG TTT GAT AAG ATG AAG AAG GAT GAT CAG ATT GCT	94
Arg Asn Ala Glu Ala Phe Asp Lys Met Lys Lys Asp Asp Gln Ile Ala	
20 25 30	
GCT GCT ATG GTT CTG AGG GGA ATG GCT AAG GAT GGG CAG TTT GCT TTG	142
Ala Ala Met Val Leu Arg Gly Met Ala Lys Asp Gly Gln Phe Ala Leu	
35 40 45	

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 47 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Pro Leu Thr Asn Pro Ile Asp Ala Ala Ile Gly Gly Ser Ala Asp Arg
1 5 10 15
Asn Ala Glu Ala Phe Asp Lys Met Lys Lys Asp Asp Gln Ile Ala Ala
20 25 30
Ala Met Val Leu Arg Gly Met Ala Lys Asp Gly Gln Phe Ala Leu
35 40 45

MICROORGANISMS	
Optional Sheet in connection with the microorganism referred to on page <u>10</u> , line <u>7</u> of the description *	
A. IDENTIFICATION OF DEPOSIT : <u>E. coli SURE 7-1 IP90</u> Further deposits are identified on an additional sheet <input checked="" type="checkbox"/> *	
Name of depositary institution * <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) * <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209 USA</u>	
Date of deposit * <u>June 27, 1997</u>	Accession Number * <u>98478</u>
B. ADDITIONAL INDICATIONS * (leave blank if not applicable). This information is continued on a separate attached sheet <input type="checkbox"/>	
C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE * (if the indications are not for all designated States)	
D. SEPARATE FURNISHING OF INDICATIONS * (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")	
E. <input checked="" type="checkbox"/> This sheet was received with the international application when filed (to be checked by the receiving Office)	
(Authorized Officer) <u>Melvin Brooks</u>	
<input type="checkbox"/> The date of receipt (from the applicant) by the International Bureau is: was _____ (Authorized Officer)	

MICROORGANISMSOptional Sheet in connection with the microorganism referred to on page 10, line 13-14 of the description**A. IDENTIFICATION OF DEPOSIT:** E. coli SURE 1-1 IP90Further deposits are identified on an additional sheet ☒

Name of depositary institution *

American Type Culture Collection

Address of depositary institution (including postal code and country) *

10801 University Boulevard
Manassas, Virginia 20110-2209 USA

Date of deposit *

June 11, 1998

Accession Number *

98768

B. ADDITIONAL INDICATIONS * (leave blank if not applicable). This information is continued on a separate attached sheet ☐**C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *** (If the indications are not for all designated States)**D. SEPARATE FURNISHING OF INDICATIONS *** (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")

E. ☒ This sheet was received with the international application when filed (to be checked by the receiving Office)**MELVIN S. BROOKS SR.**
INTERNATIONAL DIVISION

(Authorized Officer) 703-303-5163

MSB

☐ The date of receipt (from the applicant) by the International Bureau is

was

(Authorized Officer)

MICROORGANISMS

Optional Sheet in connection with the microorganism referred to on page 10, line 13-14 of the descriptionA. IDENTIFICATION OF DEPOSIT: E. coli SURE 3-1 IP90Further deposits are identified on an additional sheet ☒

Name of depository institution *

American Type Culture Collection

Address of depository institution (including postal code and country) *

10801 University Boulevard
Manassas, Virginia 20110-2209 USA

Date of deposit *

June 11, 1998

Accession Number *

98769

B. ADDITIONAL INDICATIONS * (leave blank if not applicable). This information is continued on a separate attached sheet ☐

C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE * (If the indications are not for all designated States)

D. SEPARATE FURNISHING OF INDICATIONS * (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")

E. ☒ This sheet was received with the international application when filed (to be checked by the receiving Office)MELVIN S. BROOKS SR.
INTERNATIONAL DIVISION
703-303-5163 MSB

(Authorized Officer)

☐ The date of receipt (from the applicant) by the International Bureau is *

was

(Authorized Officer)

MICROORGANISMSOptional Sheet in connection with the microorganism referred to on page 10, line 13-14 of the description ***A. IDENTIFICATION OF DEPOSIT :** E. coli SURE 6-1 IP90Further deposits are identified on an additional sheet ☒ *

Name of depository institution *

American Type Culture Collection

Address of depository institution (including postal code and country) *

10801 University Boulevard
Manassas, Virginia 20110-2209 USA

Date of deposit *

June 11, 1998

Accession Number *

98770

B. ADDITIONAL INDICATIONS * (leave blank if not applicable). This information is continued on a separate attached sheet ☐**C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *** (If the indications are not for all designated States)**D. SEPARATE FURNISHING OF INDICATIONS *** (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")

E. ☒ This sheet was received with the international application when filed (to be checked by the receiving Office)**MELVIN S. BROOKS SR.**
INTERNATIONAL DIVISION(Authorized Officer) **703-305-5163**

MSB

☐ The date of receipt (from the applicant) by the International Bureau is

was

(Authorized Officer)

MICROORGANISMS	
Optional Sheet in connection with the microorganism referred to on page <u>10</u> , line <u>13-14</u> of the description *	
A. IDENTIFICATION OF DEPOSIT : <u>E. coli SURE 9-1 IP90</u> Further deposits are identified on an additional sheet <input checked="" type="checkbox"/> *	
Name of depositary institution : <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) : <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209 USA</u>	
Date of deposit : <u>June 11, 1998</u>	Accession Number : <u>98771</u>
B. ADDITIONAL INDICATIONS : (leave blank if not applicable). This information is continued on a separate attached sheet <input type="checkbox"/>	
C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE : (If the indications are not for all designated States)	
D. SEPARATE FURNISHING OF INDICATIONS : (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")	
E. <input checked="" type="checkbox"/> This sheet was received with the international application when filed (to be checked by the receiving Office) <div style="text-align: right;">MELVIN S. BROOKS SR. INTERNATIONAL DIVISION 705-303-5163 <i>MS</i></div> <div style="text-align: center;">(Authorized Officer)</div> <div style="text-align: center;"><input type="checkbox"/> The date of receipt (from the applicant) by the International Bureau is was (Authorized Officer)</div>	

MICROORGANISMS

Optional Sheet in connection with the microorganism referred to on page 10, line 13-14 of the description *A. IDENTIFICATION OF DEPOSIT: E. coli SURE 12-1 IP90Further deposits are identified on an additional sheet ☒ *

Name of depositary institution *

American Type Culture Collection

Address of depositary institution (including postal code and country) *

10801 University Boulevard
Manassas, Virginia 20110-2209 USA

Date of deposit *

June 11, 1998

Accession Number *

98772

B. ADDITIONAL INDICATIONS * (leave blank if not applicable). This information is continued on a separate attached sheet ☐

C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE * (if the indications are not for all designated States)

D. SEPARATE FURNISHING OF INDICATIONS * (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")

E. ☒ This sheet was received with the international application when filed (to be checked by the receiving Office)MELVIN S. BROOKS SR.
INTERNATIONAL DIVISION
703-303-5163

(Authorized Officer)

MSD

☐ The date of receipt (from the applicant) by the International Bureau is:

was

(Authorized Officer)

WHAT IS CLAIMED IS:

1. A nucleic acid sequence encoding P39.5 or a fragment thereof, isolated from cellular materials with which it is naturally associated.
2. The composition according to claim 1 which is ATCC Accession No. 98478.
3. A nucleic acid sequence encoding P39.5 or a fragment thereof, which is selected from the group consisting of:
 - (a) SEQ ID NO:1;
 - (b) SEQ ID NO: 3;
 - (c) SEQ ID NO: 4;
 - (d) SEQ ID NO: 5;
 - (e) SEQ ID NO: 6;
 - (f) SEQ ID NO: 7;
 - (g) SEQ ID NO: 8;
 - (h) SEQ ID NO: 9;
 - (i) SEQ ID NO: 10;
 - (j) SEQ ID NO: 11;
 - (k) SEQ ID NO: 12;
 - (l) SEQ ID NO: 13;
 - (m) a sequence which hybridizes to any of (a) through (l) under stringent conditions;
 - (n) an allelic variant of any of (a) through (m);
 - (o) a fragment of any of (a) through (m);
 - (p) a deletion mutant of (a).

4. An isolated P39.5 protein which is expressed *in vitro* by *Borrelia* spirochetes, and has a relative molecular mass of 39,500 daltons.

5. The protein according to claim 4, comprising an amino acid sequence selected from the group consisting of:

- (a) SEQ ID NO: 2;
- (b) SEQ ID NO: 14;
- (c) a fragment of (a) or (b);
- (d) an analog of (a) or (b) characterized by having at least 80% homology with SEQ ID NO: 2 or 14; and
- (e) a homolog of (a) or (b) characterized by having at least 80% homology with SEQ ID NO: 2 or 14.

6. A recombinant protein selected from the group consisting of:

- (a) a protein comprising the amino acid sequence of SEQ ID NO: 2 or 14 or an analog, homolog or fragment thereof;
- (b) a fusion protein comprising the amino acid sequence of SEQ ID NO: 2 or 14, or an analog, homolog or fragment thereof fused to a second protein;
- (c) a fusion protein comprising the amino acid sequence of SEQ ID NO: 2 or 14 to which are added fragments that are up to 95% identical to SEQ ID NO: 2 or 14;
- (d) a deletion protein comprising the amino acid sequence of SEQ ID NO: 2 or 14 with one or more amino acids deleted therefrom.

7. A vector comprising a nucleic acid sequence encoding P39.5 or a fragment thereof under the control of suitable regulatory sequences.

8. A host cell transformed with the vector according to claim 7.

9. A method of recombinantly expressing the P39.5 gene or a fragment thereof comprising the steps of culturing a recombinant host cell transformed with a P39.5 nucleic acid sequence or a fragment thereof under conditions which permit expression of the gene.

10. A method of recombinantly expressing the P39.5 protein or a polypeptide or peptide fragment thereof comprising the steps of culturing a recombinant host cell transformed with a nucleic acid sequence encoding said protein or fragment under conditions which permit expression of said protein or peptide.

11. The method according to claim 10 further comprising the step of isolating said expressed protein from said cell or said cell medium.

12. The method according to claim 10 wherein said P39.5 protein is a fusion protein.

13. The method according to claim 10 wherein said P39.5 protein is a deletion mutant protein.

14. A method for preparing a P39.5 protein or fragment thereof comprising chemically synthesizing said protein or fragment.

15. A diagnostic reagent comprising a nucleic acid sequence selected from the group consisting of:

(a) a nucleic acid sequence encoding P39.5, isolated from cellular materials with which it is naturally associated;

(b) SEQ ID NO: 1 or a sequence complementary thereto;

(c) SEQ ID NO: 3 or a sequence complementary thereto;

(d) SEQ ID NO: 4 or a sequence complementary thereto;

(e) SEQ ID NO: 5 or a sequence complementary thereto;

- (f) SEQ ID NO: 6 or a sequence complementary thereto;
- (g) SEQ ID NO: 7 or a sequence complementary thereto;
- (h) SEQ ID NO: 8 or a sequence complementary thereto;
- (i) SEQ ID NO: 9 or a sequence complementary thereto;
- (j) SEQ ID NO: 10 or a sequence complementary thereto;
- (l) SEQ ID NO: 11 or a sequence complementary thereto;
- (m) SEQ ID NO: 12 or a sequence complementary thereto;
- (n) SEQ ID NO: 13 or a sequence complementary thereto;
- (o) a sequence which hybridizes to any of (a) through (n)

under stringent conditions;

- (p) an allelic variant of any of (a) through (o);
- (q) a fragment of any of (a) through (o) comprising at least

15 nucleotides in length;

- (r) a deletion mutant of (a), (b) or (n); and
- (s) a sequence encoding P39.5 or a fragment thereof fused

to a sequence encoding a second protein;

and a detectable label which is associated with said sequence.

16. An isolated antibody which is directed against P39.5 or a fragment thereof.

17. The antibody according to claim 16 produced by administering to a vertebrate host a protein or fragment selected from the group consisting of P39.5, P7-1, P1-1, P3-1, P6-1, P9-1 and P12-1, said antibody capable of killing IP90 spirochetes *in vitro* by antibody-dependent, complement-mediated killing.

18. The antibody according to claim 16, isolated by immunizing said host with the protein of claim 6.

19. The antibody according to claim 16 which is selected from the group consisting of a chimeric antibody, a humanized antibody, a monoclonal antibody and a polyclonal antibody.
20. An antibody isolated by affinity purifying antiserum generated during an infection of rhesus monkeys with JD1 spirochetes using as immunoabsorbant the *Borrelia* P39.5 protein or a fragment thereof.
21. An anti-idiotypic antibody specific for the antibody of claim 16.
22. A diagnostic reagent comprising the antibody according to claim 16 and a detectable label.
23. A vaccine composition comprising an effective amount of a P39.5 protein, fusion protein or fragment thereof and a pharmaceutically acceptable carrier.
24. The composition according to claim 23 wherein said fragment is selected from the group consisting of P7-1, P1-1, P3-1, P6-1, P9-1, and P12-1.
25. The composition according to claim 23 wherein said composition comprises at least one other *B. burgdorferi* antigen or fragment thereof.
26. The composition according to claim 25 wherein said other antigen is selected from the group consisting of OspA, OspB, OspC, BmpA, BmpB, BmpC, BmpD and fragments or variants thereof.
27. The composition according to claim 23 wherein said composition comprises at least one other protein or fragment thereof which has a sequence homologous to that of P39.5 or a fragment thereof.

28. The composition according to claim 23 comprising a mixture of individual proteins.

29. The composition according to claim 25 wherein said P39.5 protein or fragment and said other antigen are in the form of a fusion protein.

30. A method of vaccinating a human or animal against Lyme Disease comprising administering to said human or animal a composition comprising an effective amount of the composition of claim 23.

31. A method for diagnosing Lyme borreliosis in a human or animal comprising the steps of incubating an anti-P7-1 or anti-39.5 antigen or a homolog thereof with a sample of biological fluids from a human or animal to be diagnosed, wherein in the presence of *B. burgdorferi* an antigen-antibody complex is formed, and subsequently analyzing said fluid sample for the presence of said complex.

32. A therapeutic composition useful in treating humans or animals with Lyme disease comprising at least one anti-P39.5 or anti-P7-1 antibody and a suitable pharmaceutical carrier.

33. A method for treating Lyme Disease in a vertebrate host comprising administering an effective amount of a composition according to claim 32.

34. A kit for diagnosing infection with *B. burgdorferi* in a human or animal comprising a P39.5 protein or fragment thereof or an anti-P39.5 antibody of claim 16.

35. A vaccine useful in the prophylaxis of Lyme Disease comprising a surface antigen that is expressed by the spirochete when it resides in the vertebrate host.

36. A method of identifying compounds which specifically bind to P39.5 or a fragment thereof, comprising the steps of contacting said P39.5 protein or fragment with a test compound to permit binding of the test compound to P39.5; and determining the amount of test compound which is bound to P39.5.

37. A compound identified by the method of claim 36.

38. A nucleic acid sequence encoding a protein or a fragment thereof of the *Borrelia* cassette string, isolated from cellular materials with which it is naturally associated, and selected from the group consisting of 1-1, 3-1, 6-1, 9-1 and 12-1.

39. A protein or a fragment thereof of a *Borrelia* cassette string, isolated from cellular materials with which it is naturally associated, and selected from the group consisting of P1-1, P3-1, P6-1, P7-1, P9-1 and P12-1.

40. A vector comprising a nucleic acid sequence encoding a *Borrelia* cassette string protein or fragment thereof under the control of suitable regulatory sequences.

41. A host cell transformed with the vector according to claim 40.

42. A method of recombinantly expressing a *B. garinii* cassette string protein or a fragment thereof comprising the steps of culturing a recombinant host cell transformed with a *B. garinii* cassette string nucleic acid sequence or a fragment thereof under conditions which permit expression of said sequence.

43. A method of recombinantly expressing a *B. garinii* cassette string protein or peptide fragment thereof comprising the steps of culturing a recombinant host cell transformed with a nucleic acid sequence encoding said protein or fragment under conditions which permit expression of said protein or peptide.

44. The method according to claim 43 further comprising the step of isolating said expressed protein from said cell or said cell medium.

45. The method according to claim 43 wherein said *Borrelia* cassette string protein or peptide fragment is a fusion protein or a deletion mutant protein.

46. A method for preparing a *B. garinii* cassette string protein or peptide fragment comprising chemically synthesizing said protein or fragment.

47. An isolated anti-*B. garinii* cassette string protein antibody.

48. The antibody according to claim 47 produced by administering to a vertebrate host a *B. garinii* cassette string protein or fragment.

49. The antibody according to claim 48, isolated by affinity purifying antiserum generated during an infection of rhesus monkeys with JD1 spirochetes using as immunoabsorbant a *Borrelia* cassette string protein.

50. The antibody according to claim 47, isolated by immunizing said host with the protein of claim 39 or a mixture of said cassette string proteins.

51. The antibody according to claim 47 which is selected from the group consisting of a chimeric antibody, a humanized antibody, a monoclonal antibody and a polyclonal antibody.

52. An anti-idiotypic antibody specific for the antibody of claim 47.
53. A diagnostic reagent comprising the antibody according to claim 47 and a detectable label.
54. A vaccine composition comprising an effective amount of at least one *Borrelia* cassette string protein, fusion protein or fragment thereof and a pharmaceutically acceptable carrier.
55. The composition according to claim 54 comprising a mixture of different *Borrelia* cassette string proteins or fragments.
56. The composition according to claim 54 comprising at least one other *B. burgdorferi* antigen or fragment thereof.
57. The composition according to claim 56 wherein said other antigen is selected from the group consisting of OspA, OspB, OspC, BmpA, BmpB, BmpC, BmpD and fragments or variants thereof.
58. The composition according to claim 54 comprising P39.5 or at least one other protein or fragment thereof which has a sequence homologous to P39.5.
59. A method of vaccinating a human or animal against Lyme Disease comprising administering to said human or animal a composition comprising an effective amount of the composition of claim 54.

60. A method for diagnosing Lyme borreliosis in a human or animal comprising the steps of incubating an anti-*Borrelia* cassette string protein antibody with a sample of biological fluids from a human or animal to be diagnosed, wherein in the presence of *B. burgdorferi* an antigen-antibody complex is formed, and subsequently analyzing said fluid sample for the presence of said complex.

61. A therapeutic composition useful in treating humans or animals with Lyme disease comprising at least one *Borrelia* cassette string protein antibody, or fragment antibody and a suitable pharmaceutical carrier.

62. A method for treating Lyme Disease in a vertebrate host comprising administering an effective amount of a composition according to claim 61.

63. A kit for diagnosing infection with *B. burgdorferi* in a human or animal comprising a *Borrelia* cassette string protein or fragment thereof or an antibody thereto.

64. A method of identifying compounds which specifically bind to a *Borrelia* cassette string protein or fragment thereof, comprising the steps of contacting said protein or fragment with a test compound to permit binding of the test compound to said cassette string protein or fragment; and determining the amount of test compound which is bound to said protein or fragment.

65. A compound identified by the method of claim 64.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07K 14/20, A61K 39/02, C12N 15/31	A1	(11) International Publication Number: WO 99/00413 (43) International Publication Date: 7 January 1999 (07.01.99)
(21) International Application Number: PCT/US98/13551 (22) International Filing Date: 29 June 1998 (29.06.98) (30) Priority Data: 60/051,271 30 Dec 99 / 30 June 1997 (30.06.97) <i>US</i> (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/051,271 (CIP) Filed on 30 June 1997 (30.06.97) (71) Applicant (for all designated States except US): THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND [US/US]; 1430 Tulane Avenue, New Orleans, LA 70112-2699 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): ✓ PHILIPP, Mario, T. [DE/US]; 248 Shaunell Drive, Mandeville, LA 70448 (US). (74) Agents: BAK, Mary, E. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).		(81) Designated States: AU, BR, CA, CN, CZ, HU, ID, IL, JP, KR, MX, NO, NZ, PL, TR, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: SURFACE ANTIGENS AND PROTEINS USEFUL IN COMPOSITIONS FOR THE DIAGNOSIS AND PREVENTION OF LYME DISEASE ✓ (57) Abstract A novel isolated <i>Borrelia burgdorferi</i> sensu lato surface antigen is characterized by a relative molecular mass of 39.5 kDa. This antigen is expressed <i>in vitro</i> by spirochetes of a <i>B. burgdorferi</i> sensu lato strain. This antigen induces antibodies which kill spirochetes of a <i>B. burgdorferi</i> sensu lato strain by ADCK <i>in vitro</i> . Novel <i>Borrelia</i> cassette string protein or fragments thereof are also useful, as is the P39.5 protein in diagnosing Lyme disease and in compositions for treatment or prophylaxis thereof.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/13551

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 14/20, A61K 39/02, C12N 15/31

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, C12N, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Cell., Volume 89, No 2, April 1997, Jing-Ren Zhang et al, "Antigenic Variation in Lyme Disease Borreliae by Promiscuous Recombination of VMP-like Sequence Cassettes"	1-3,6-65
	--	
X	EP 0465204 A2 (AMERICAN HOME PRODUCTS CORPORATION), 8 January 1992 (08.01.92), see claims and the whole document	1-2,4-6,23, 30,35,54-59, 61-62
	--	
A	Infection and Immunity, Volume 64, No 4, April 1996, Ramesh Ramamoorthy et al, "Molecular Characterization, Genomic Arrangement, and Expression of bmpD, a New Member of the bmp Class of Genes Encoding Membrane Proteins of Borrelia burgdorferi" page 1259 - page 1264	1-6
	--	

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

27 October 1998

Date of mailing of the international search report

13.11.98

Name and mailing address of the ISA/



European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 cpo nl,
Fax: (+31-70) 340-3016

Authorized officer

PATRICK ANDERSSON

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Zhang J.-R., et al: "Kinetics and in vivo induction of vlsE antigenic variation in <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ databases. Accession no. AF034515, 2 June 1998 --	1-3,6-65
P,X	Kawabata H. et al: "Genetic and immunological analyses of Vls (VMP-like sequences) of <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ databases. Accession no. AB011063, 13 March 1998 --	1-3,6-65
P,X	Zhang J.-R. et al: "Kinetics and in vivo induction of vlsE antigenic variation in <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ databases. Accession no. AF034525, 2 June 1998 --	1-3,6-65
P,X	Zhang J.R. et al: "Kinetics and In vivo induction of genetic variation of vlsE in <i>Borrelia burgdorferi</i> ", EMBL/GenBank/DDBJ Databases. Accession no. AF034523, 2 June 1998 -- -----	1-3,6-65

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 13551

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 30,33 and 62
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.: 1-65
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful international Search can be carried out, specifically:

Please see FURTHER INFORMATION SHEET
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos. 1-65

As no functional or structural property shared by P39.5 proteins from strains other than *Borrelia garinii* IP90 is disclosed and in the absence of a definition of "cassette string protein", the claims are not considered to be clear and concise, see PCT-Article 6.

The search has been limited to a protein from *Borrelia garinii* strain IP90 having a apparent molecular mass of 39,5 kDa, and the sequences disclosed. Accordingly, the search concerning related subject-matters has been limited to the subjects related to the searched proteins.

Information on patent family members

05/10/98

International application No.

PCT/US 98/13551

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0465204 A2	08/01/92	AU 8014691 A	09/01/92
		CA 2046025 A	07/01/92
		JP 4297424 A	21/10/92
		PT 98202 A	29/05/92
